

1 **PBP1 of *Staphylococcus aureus* has multiple essential functions in cell**

2 **division**

3

4 Katarzyna Wacnik<sup>1,2</sup>, Vincenzo A Rao<sup>3</sup>, Xinyue Chen<sup>2,4</sup>, Lucia Lafage<sup>1,2</sup>, Manuel Pazos<sup>5</sup>,

5 Simon Booth<sup>3</sup>, Waldemar Vollmer<sup>5</sup>, Jamie K Hobbs<sup>2,4</sup>, Richard J Lewis<sup>3‡</sup> and Simon J

6 Foster<sup>1,2\*</sup>

7

8 <sup>1</sup> School of Biosciences, University of Sheffield, Sheffield, UK

9 <sup>2</sup> The Florey Institute for Host-Pathogen Interactions, University of Sheffield, Sheffield, UK

10 <sup>3</sup> Biosciences Institute, Newcastle University, Newcastle upon Tyne, UK.

11 <sup>4</sup> Department of Physics and Astronomy, University of Sheffield, Sheffield, UK

12 <sup>5</sup> Centre for Bacterial Cell Biology, Bioscience Institute, Newcastle University, Newcastle  
13 upon Tyne, UK.

14

15 ‡ Current address: The Royal Society for the Protection of Birds, The Lodge, Sandy,

16 Bedfordshire SG19 2DL

17 \* To whom correspondence should be sent. E-mail: [s.foster@sheffield.ac.uk](mailto:s.foster@sheffield.ac.uk).

## 18 **Abstract**

19 Bacterial cell division is a complex process requiring the coordination of multiple  
20 components, to allow the appropriate spatial and temporal control of septum formation and  
21 cell scission. Peptidoglycan (PG) is the major structural component of the septum, and our  
22 recent studies in the human pathogen *Staphylococcus aureus* have revealed a complex, multi-  
23 stage PG architecture that develops during septation. Penicillin binding proteins (PBPs) are  
24 essential for the final steps of PG biosynthesis – their transpeptidase activity links together  
25 the peptide sidechain of nascent glycan strands together. PBP1 is required for cell division in  
26 *S. aureus* and here we demonstrate that it has multiple essential functions associated with its  
27 enzymatic activity and as a regulator of division. Loss of PBP1, or just its C-terminal PASTA  
28 domains, results in cessation of division at the point of septal plate formation. The PASTA  
29 domains can bind PG and thus coordinate the cell division process. The transpeptidase  
30 activity of PBP1 is also essential but its loss leads to a strikingly different phenotype of  
31 thickened and aberrant septa, which is phenocopied by the morphological effects of adding  
32 the PBP1-specific  $\beta$ -lactam, meropenem. Together these results lead to a model for septal PG  
33 synthesis where PBP1 enzyme activity is responsible for the characteristic architecture of the  
34 septum and PBP1 protein molecules coordinate cell division allowing septal plate formation.

35

## 36 **Introduction**

37 Peptidoglycan (PG) is the major structural component of the bacterial cell wall and is  
38 essential for maintaining cell shape, integrity and survival (Silhavy et al., 2010; Turner et al.,  
39 2014; Vollmer et al., 2008). The final assembly stages of assembly of this large polymeric  
40 molecule are mediated by penicillin-binding proteins (PBPs), key PG synthases that, through  
41 their transglycosylase (TG) and transpeptidase (TP) activities, polymerise glycan chains and  
42 cross-link them into a mesh-like hydrogel (Pasquina-Lemonche et al., 2020; Typas et al.,

43 2011). Since the cell wall is essential for maintaining bacterial life, PBPs and PG synthesis  
44 are a target of some of the most important antibiotics,  $\beta$ -lactams (penicillins) and  
45 glycopeptides (vancomycin) (Schneider & Sahl, 2010; Zapun et al., 2008). The major human  
46 pathogen *Staphylococcus aureus* has a minimalist PBP system as it encodes only four PBPs,  
47 PBP1 to PBP4 (Pinho et al., 2013). Only PBP1 (class B PBP with only TP activity, bPBP)  
48 and PBP2 (class A bifunctional PBP with both TG and TP activities, aPBP) are essential and  
49 sufficient for septal and peripheral PG synthesis in *S. aureus* (Lund et al., 2018; Pinho et al.,  
50 2013). PBP2 is the major PG synthase of *S. aureus*, and the septal formation activity of PBP2  
51 is mediated by its substrate, Lipid II (Pinho & Errington, 2005). Although PBP2 is essential,  
52 loss of its TP activity can be compensated for by a horizontally acquired class B PBP2A in  
53 methicillin-resistant *S. aureus* (MRSA) (Pinho, Filipe, et al., 2001). PBP2A, however, cannot  
54 replace PBP1, whose loss is detrimental to the viability of *S. aureus* (Pereira et al., 2007).  
55 PBP1 and PBP3 form cognate pairs with the monofunctional TGs, FtsW and RodA,  
56 belonging to the SEDS (shape, elongation, division and sporulation) family (Meeske et al.,  
57 2016) to facilitate septum formation (PBP1-FtsW) and to maintain the prolate cell shape  
58 (PBP3-RodA) of *S. aureus*, respectively (Reichmann et al., 2019). PBP4 is a class C PBP  
59 with D,D-carboxypeptidase activity (cPBP) and has a TP activity that contributes to the high-  
60 level cross-linking of PG and MRSA resistance to  $\beta$ -lactams (Loskill et al., 2014; Srisuknimit  
61 et al., 2017).

62

63 Although *S. aureus* PBPs have been studied over many years, the specific roles of PBP1 in  
64 cell division, PG synthesis and architecture have remained elusive. Previous studies have  
65 shown that whilst PBP1 is essential, its TP activity is not, implying another role (Pereira et  
66 al., 2007; Reichmann et al., 2019). However, this work was performed in an MRSA  
67 background that contains PBP2A, encoded by *mecA*, which is non-native to *S. aureus* (Pinho,

68 de Lencastre, et al., 2001). Whilst PBP2A cannot replace PBP1, how these proteins interact is  
69 unknown. We have recently shown that the presence of *mecA* has a profound effect on  
70 cellular physiology (Panchal et al., 2020). Thus it is important to understand individual and  
71 combined roles of *S. aureus* PBPs both in the presence and absence of the exogenous PBP2A,  
72 as the vast majority of *S. aureus* infections are caused by methicillin sensitive strains.

73

## 74 **Results**

### 75 ***S. aureus* PBP1 PASTA domains are essential for growth and PBP1 functionality**

76 PBP1 has a cytoplasmic N-terminal region, a membrane spanning sequence, an  
77 exocyttoplasmic dimerization domain and a C-terminal region consisting of the TP domain  
78 and two PASTA domains (for penicillin-binding protein and serine/threonine kinase  
79 associated domain) (Yeats et al., 2002). We created a set of conditional mutants of *pbp1* to  
80 investigate the role of PBP1 in cell division and PG synthesis. An ectopic copy of *pbp1* under  
81 the control of the *Pspac* promoter (*P<sub>spac</sub>-pbp1*) was placed at the lipase locus (*geh::P<sub>spac</sub>-pbp1*)  
82 of *S. aureus* SH1000, and a series of changes were made in this genetic background at the  
83 native *pbp1* locus: (i) an in-frame deletion of *pbp1* ( $\Delta pbp1$ ), (ii) a deletion of the region  
84 encoding the two PASTA domains (*pbp1* $\Delta$ <sub>PASTA</sub>), and (iii) the substitution of the catalytic  
85 Ser314 to Ala in the TP domain (*pbp1*<sup>\*</sup>) (Fig. 1a, b). We examined the essentiality of PBP1,  
86 the PASTA domains and the active TP domain with these mutants. Depletion of PBP1 via  
87 IPTG removal (Fig. 1c and Fig. 1 – figure supplement 1a, b) resulted in cell death,  
88 confirming the essentiality of PBP1 (Fig. 1c, d and Fig. 1 – figure supplement 1c, d).  
89 Deletion of the PASTA domains also led to growth inhibition and more than 99% cell death  
90 within 4 h (Fig. 1d and Fig. 1 – figure supplement 1c, d). Importantly, this phenotype was not  
91 associated with PBP1 $\Delta$ <sub>PASTA</sub> instability (Fig. 1c and Fig. 1 – figure supplement 1a) or loss of  
92 its ability to bind its substrate analogue BocillinFL (Fig. 1 – figure supplement 1b). By

93 contrast, deletion of the PASTA domains of *Streptococcus pneumoniae* PBP2x, a PBP1  
94 orthologue, resulted in a complete loss of BocillinFL binding (Maurer et al., 2012). These  
95 results indicate the PASTA domains are essential for *S. aureus* growth and PBP1  
96 functionality but not its enzymatic activity.  
97 During construction of the *pbp1\** mutant we obtained, by serendipity, a *pbp1*<sub>STOP</sub> mutant in  
98 which a SNP in the codon for Glu292 resulted in its replacement with a premature stop codon  
99 and the truncation of the entire TP and PASTAs region of PBP1 (Fig. 1 – figure supplement  
100 1e, f). However, immunoblot analysis using anti-PBP1 sera could not confirm the presence of  
101 the PBP1<sub>STOP</sub> protein in the *pbp1*<sub>STOP</sub> mutant (Fig. 1 – figure supplement 1g), suggesting that  
102 stability of the N-terminal domain of PBP1 is dependent on its C-terminus.  
103 Although inactivation of PBP1 TP activity (PBP1\*) did not affect protein stability (Fig. 1c),  
104 it did remove the ability of PBP1 to bind BocillinFL (Fig. 1 – figure supplement 1b). The loss  
105 of PBP1 TP activity resulted in severely compromised growth on solid media (Fig. 1d and  
106 Fig. 1 – figure supplement 1c) and reduced cellular viability in liquid culture (Fig. 1e and Fig.  
107 1 – figure supplement 1d). Thus, the TP activity of PBP1 is required for growth in the  
108 SH1000 background. Inactivation of the PBP1 TP activity was reported previously not to  
109 affect growth in the COL strain background (Reichmann et al., 2019). The differences in the  
110 necessity for the PBP1 TP activity could result from COL being MRSA whereas SH1000 is a  
111 methicillin sensitive *S. aureus* (MSSA).

112

### 113 **PBP1 TP activity is crucial in MSSA but not in MRSA**

114 We have recently developed a set of defined strains where high-level  $\beta$ -lactam resistance of  
115 MRSA is mediated by *mecA* encoding PBP2A and a mutation in either *rpoB* or *rpoC*  
116 (Panchal et al., 2020). This combination of genetic alterations (*mecA*<sup>+</sup> *rpoB*) are present in  
117 COL (Panchal et al., 2020). To test if the apparent disparity in PBP1 role is associated with

118 MRSA, we developed a high-level resistant mutant of *pbp1*\* in the well-characterised *S.*  
119 *aureus* SH1000 by adding the *mecA rpoB*<sup>H929Q</sup> to the MSSA *pbp1*\* mutant, resulting in  
120 SH1000<sub>MRSA</sub> *pbp1*\* (Fig. 1 – figure supplement 2a). Inactivating PBP1 TP did not affect the  
121 ability of SH1000<sub>MRSA</sub> *pbp1*\* to grow in the absence of IPTG, whereas *pbp1* depletion led to  
122 growth inhibition in the isogenic  $\Delta$ *pbp1* MSSA and MRSA strains (Fig. 1d, e and Fig. 1 –  
123 figure supplement 2b-d). Thus, the fundamental role of PBP1 in growth and division can only  
124 be studied in an MSSA background as otherwise the role of PBP1 can be confounded by the  
125 presence of the MRSA resistance apparatus.

126

### 127 **PBP1 PASTA domains are required for septum progression**

128 PG synthesis still occurred in  $\Delta$ *pbp1*, *pbp1* <sub>$\Delta$ PASTA</sub> and *pbp1*\* in the absence of IPTG, despite  
129 cell growth inhibition, as measured by the incorporation of the fluorescent D-amino acid  
130 derivative HADA (Fig. 2a). This was not a consequence of the non-synthesis, exchange  
131 reaction carried out by PBP4 as it occurred in *pbp4* as well as with the dipeptide ADA-DA  
132 (Kuru et al., 2019; Lund et al., 2018) (Fig. 2 – figure supplement 1). All variants increased in  
133 cell volume upon depletion of *pbp1*, whereas *pbp1* <sub>$\Delta$ PASTA</sub> was enlarged by almost twice as  
134 much as  $\Delta$ *pbp1* and *pbp1*\* (Fig. 2a, b and Fig. 2 – figure supplement 2a). Despite differences  
135 in cell size, both  $\Delta$ *pbp1* and *pbp1* <sub>$\Delta$ PASTA</sub> decreased the number of cells with complete septa  
136 (Fig. 2a, c). Transmission electron microscopy (TEM) showed that more than 80% of the  
137 population had growth defects including cell wall thickening, PG blebs, mis-shapen and/or  
138 multiple, incomplete septa. (Fig 2d, e and Fig. 2 – figure supplement 2b, c). Such septa had  
139 abnormally thick bases and sharply pointed leading edges, suggesting that cell growth arrest  
140 was not due to a lack of septal initiation but instead arrest of inward septum progression.  
141 Atomic force microscopy (AFM) has revealed previously that the first step in cell division is  
142 the formation of a PG feature called the “piecrust”, prior to the septal plate (Turner et al.,

143 2010). The *S. aureus* septal plate has two PG architectures: disordered mesh facing the cell  
144 membrane and concentric rings in the septum core (Pasquina-Lemonche et al., 2020). Here  
145 lack of PBP1 or the PBP1 PASTA domains led to formation of more than one, and often  
146 misplaced, piecrust. These mutations also caused an increase in unfinished septal annuli and  
147 alterations in the ring surface architecture (Fig 2f and Fig. 2 – figure supplement 3a, c –  
148 arrowheads), a characteristic feature of the division plane, freshly revealed immediately after  
149 cell scission (Pasquina-Lemonche et al., 2020). Thus, depletion of PBP1 did not stop septum  
150 initiation but the loss of the PASTA domains was enough to cause formation of irregular  
151 piecrusts, arrest septal plate formation and lead to an altered septal PG architecture.

152

### 153 **PBP1 TP activity regulates septal PG architecture**

154 The *pbp1\** mutant gave a novel phenotype quite distinct from loss of entire PBP1 or the  
155 PASTA domains. Inactivation of PBP1 TP activity did not prevent initiation and closing of  
156 the septa, but instead resulted in accumulation of cells with aberrant septa and separation  
157 defects in about 80% of the population (Fig. 2a, c, e). The septa in such cells had a rounded  
158 leading edge, were curved, abnormally thick (Fig. 2d, e and Fig. 2 – figure supplement 2b, c),  
159 had agglomerations of mesh-like material close to the septal centre in addition to irregular  
160 piecrusts as observed by AFM (Fig. 2f and Fig. 2 – figure supplement 3a, b). The  
161 intracellular agglomerations are PG as they stain heavily with HADA and ADA-DA (Fig. 2a  
162 and Fig. 2 – figure supplement 1c, f) and could be observed in purified sacculi (Fig. 2f and  
163 Fig. 2 – figure supplement 3b). No ring architecture, only mesh structured PG could be  
164 observed on the surface of the *pbp1\** mutant. Importantly, using fluorescence microscopy the  
165 *pbp1\* pbp3 pbp4* mutant, in which PBP2 is the only active TP, presented a similar phenotype  
166 upon IPTG removal as *pbp1\**, exemplified by misshapen septa and agglomerations of PG  
167 material marked by HADA (Fig. 2 – figure supplement 2d). Therefore, septal synthesis and

168 progression still occurred in the *pbp1*\* mutant, however, they resulted from PBP2  
169 transpeptidase activity and potentially the transglycosylase activity of FtsW.  
170  
171 The *pbp1*\* phenotype occurred specifically because of the loss of the TP activity of this  
172 essential enzyme. This phenotype is mirrored by the mode of action of  $\beta$ -lactam antibiotics,  
173 which bind to and inhibit the TP activity of PBPs (Schneider & Sahl, 2010). Our results  
174 suggest that PBP1 TP activity has a specific role in septal plate formation and without this the  
175 septum is mis-shapen. The conditional lethal strains made here allow for functional analysis  
176 of the genes concerned. However, phenotypes tend to accumulate on depletion of the wild-  
177 type protein over time confusing the precise roles for individual components. To  
178 independently corroborate the role of the TP activity of PBP1 we utilized an approach to  
179 directly, and selectively, inhibit its activity. Meropenem (MEM) has a higher affinity for  
180 PBP1 than PBP2 (Berti et al., 2013; Yang et al., 1995) and, therefore, we hypothesised that  
181 its effect on *S. aureus* would match *pbp1*\*. In a MEM-titration, treatment with 1x MIC MEM  
182 was sufficient to lead to cell death and a significant increase in SH1000 WT cell volume after  
183 1 h (Fig. 3a, b and Fig. 3 – figure supplement 1a). More than 70% of MEM treated cells had  
184 growth defects that manifested as aberrantly shaped septa and accumulation of PG as shown  
185 by HADA labelling (Fig. 3a, c, d Fig. 3 – figure supplement 1c, e), similar to observations  
186 made with the *pbp1*\* mutants (Fig. 2a, c-e, Fig. 2 – figure supplement 1c, f). The MEM  
187 phenotype of malformed septa was not linked to PBP3 or PBP4 as it was also observed in the  
188 corresponding double mutant (Fig. 3c, d and Fig. 3 – figure supplement 1b, d, f), which  
189 corroborated the role of PBP2 in misshapen septal genesis.

190

191 **PASTA domains mediate PBP1 interaction with division components**



192 The morphologies of the  $\Delta pbp1$  and  $pbp1_{\Delta PASTA}$  mutants resemble *S. aureus* depleted of  
193 DivIB in which EzrA and FtsZ form multiple rings and the synthesis of the cross wall is  
194 blocked, despite the normal recruitment of early cell division proteins and piecrust formation  
195 (Bottomley et al., 2014). In the  $\Delta pbp1$  *ezrA-gfp* mutant, EzrA, which here acts as an early cell  
196 division marker, was localised at midcell in the majority of cells and formed additional arcs  
197 or rings in 33.5% of the population (Fig. 4a, d). Multiple EzrA rings were observed in 42.7%  
198 of the  $pbp1_{\Delta PASTA}$  *ezrA-gfp* mutant cells (Fig. 4b, d), supporting the requirement for PBP1  
199 PASTA domains for correct selection of the division site. Alternatively, the multiple division  
200 rings could result from a lack of the septal progression whereby the unproductive division  
201 machinery results in futile additional alternative initiation attempts, suggesting that PASTA  
202 domains are involved in the progression from piecrust to septal plate formation. While the  
203 number of cells with complete septa (EzrA-GFP visible as a line or focus) reduced by at least  
204 6-fold in  $\Delta pbp1$  *ezrA-gfp* and  $pbp1_{\Delta PASTA}$  *ezrA-gfp*, it only halved in  $pbp1^*$  *ezrA-gfp* (12.5%  
205 to 6.3% of  $pbp1^*$  *ezrA-gfp* in +/-IPTG, respectively; Fig. 4c, d), confirming that septum  
206 progression, although reduced, still occurred when PBP1 TP was inactive implying that TP  
207 activity is necessary for correct septal architecture during cell division.

208  
209 The cell wall of Gram-positive bacteria is decorated with wall teichoic acid (WTA)  
210 glycopolymers (Neuhaus & Baddiley, 2003). WTA regulates cell shape, ion homeostasis,  
211 autolytic enzymes, growth and division (Swoboda et al., 2010). In *S. aureus*, WTA plays a  
212 crucial role in virulence, MRSA resistance to  $\beta$ -lactam antibiotics, PBP4 localisation at the  
213 septum and PG cross-linking (Atilano et al., 2010; Campbell et al., 2011; Farha et al., 2013;  
214 Weidenmaier et al., 2005). Loss of WTA also results in a proportion of cells with aberrant  
215 septa (Campbell et al., 2011) suggesting a link with PBP1 function. Loss of *tarO* (leading to a  
216 lack of WTA) caused minor cell division defects in SH1000 (Fig. 4 – figure supplement 1a, e,

217 f). Combining *tarO* with the mutations in *pbp1* exacerbated the observed morphological  
218 defects, with the appearance of distinct septal and off-septal PG foci appeared (marked with  
219 HADA) in  $\Delta pbp1 tarO$  and  $pbp1_{\Delta PASTA} tarO$  (Fig. 4 – figure supplement 1b-f), demonstrating  
220 that both WTA and PBP1 are involved in cell cycle control in parallel.

221

222 As PBP1 PASTA has a role in the regulation of septal plate formation, this may be  
223 determined by interacting with other protein components. In order to examine this hypothesis  
224 we performed a bacterial two-hybrid assay, in which PBP1 has previously been found to have  
225 multiple interactions (Steele et al., 2011). Truncation of the PASTA domains not only  
226 reduced *S. aureus* PBP1 interaction with DivIB but also with FtsW, whilst recognition of  
227 other known interacting partners of PBP1 (EzrA, PBP2 and DivIC) were unaffected by the  
228 PASTA truncation (Fig. 5 – figure supplement 1a, b), suggesting that these wider interactions  
229 involve the N-terminal domain of PBP1.

230

### 231 **PBP1 PASTA domains bind peptidoglycan**

232 Impaired interaction with DivIB could be one explanation for why cells depleted of PBP1  
233 PASTA domains initiate irregular piecrusts and septation defects accrue as a consequence.  
234 PASTA domains have long been associated with PG binding because of work performed  
235 mainly on serine/threonine protein kinases (STPK) (Mir et al., 2011; Shah et al., 2008;  
236 Squeglia et al., 2011; Yeats et al., 2002). Therefore, we assessed whether *S. aureus* PBP1 and  
237 its PASTA domains could recognise PG by measuring their affinities for *S. aureus* cell wall  
238 PG with or without WTA (+/-WTA) with a semi-quantitative fluorescence binding assay  
239 (Bottomley et al., 2014) and *S. aureus* PBP1 derivatives produced in *Escherichia coli* (Fig. 5a  
240 and Fig. 5 – figure supplement 1c). Both *Sa*PBP1 ( $K_d$   $19 \pm 4$  nM (+WTA),  $115 \pm 21$  nM (-  
241 WTA)) and its PASTA domains (*Sa*PASTA<sub>PBP1</sub>;  $K_d$   $198 \pm 42$  nM (+WTA),  $109 \pm 23$  nM (-

242 WTA) bound PG (Fig. 5b). Inactive *Sa*PBP1\* was still able to bind PG with a preference for  
243 PG with WTA present ( $K_d$   $53 \pm 8$  nM (+WTA),  $227 \pm 46$  nM (-WTA); Fig. 5b), similar to  
244 active *Sa*PBP1. Although removal of the PASTA domains did not abolish BocillinFL binding  
245 (Fig. 5 – figure supplement 1c), it considerably reduced the ability of *Sa*PBP1 $\Delta$ PASTA to bind  
246 PG and binding was completely abolished in the presence of WTA ( $K_d$   $>2000$  nM (+WTA),  
247  $440 \pm 57$  nM (-WTA); Fig. 5b). By contrast, the PASTA domains (*Sa*PASTA<sub>PBP1</sub>) on their  
248 own bind to *S. aureus* PG but are incapable of binding BocillinFL (Fig. 5b and Fig. 5 – figure  
249 supplement 1c). These results demonstrate unequivocally that PBP1 is a PG binding protein,  
250 and the PASTA domains have a dominant role in this interaction. Sequence conservation  
251 analysis of PASTA domains revealed the presence of either Arg or Glu residues in  
252 classifying a PASTA domain as a PG-binder (Calvanese et al., 2017). The PASTA domains  
253 of *S. aureus* PBP1 each have proline at the equivalent positions (residues Pro603 and Pro661)  
254 and thus PBP1 would be predicted as a non-PG binder, which clearly is not the case from the  
255 experimental evidence presented herein. Not only have we demonstrated the existence of  
256 such an interaction but we have also quantified it, suggesting that the predicted significance  
257 of conserved Arg or Glu residues with regard to PG binding is either only relevant to PASTA  
258 domains found in STPKs, linear arrangements of tandem PASTA repeats, or is too simplistic  
259 a prediction for proteins with multiple and complex functions like PBPs.

260

261 To gain a better understanding of the role of the PASTA domains in *S. aureus* PBP1  
262 (*Sa*PASTA<sub>PBP1</sub>), we determined their structure by X-ray crystallography. Soluble  
263 recombinant protein was obtained in high yield from the cytoplasm of *E. coli* cells and well-  
264 ordered crystals were subsequently produced that diffracted to a maximum resolution of 1.78  
265 Å (Appendix Table 4). The structure was solved by molecular replacement using the  
266 corresponding PASTA domains present in *Sp*PBP2x from PDB entry 5OAU (Bernardo-

267 García et al., 2018), which shares 26% sequence identity with *Sa*PASTA<sub>PBP1</sub>. The asymmetric  
268 unit contains two monomers (labelled A and B), each forming a 2-layer sandwich comprising  
269 an  $\alpha$ -helix and a three-stranded antiparallel  $\beta$ -sheet, distinct from the TP domain (Fig. 5c).  
270 Clear and continuous electron density allowed the modelling and unambiguous assignment of  
271 both PASTA domains (Fig. 5c). When *Sa*PASTA<sub>PBP1</sub> is compared with other structures  
272 deposited in the PDB using *DALI* (Holm, 2020), the top hit identified was *S. pneumoniae*  
273 PBP2x (Z-score; 15.7), showing a significant conservation of the PASTA fold, despite low  
274 sequence identity (Fig. 5c). Unlike the linear arrangement observed for PASTA domains in  
275 serine/threonine kinases (Barthe et al., 2010; Ruggiero et al., 2011), *Sa*PASTA<sub>PBP1</sub> adopts a  
276 compact upside-down globular arrangement (Fig. 5c). The arrangement of the two PASTA  
277 domains solved here, in isolation from the TP domain in comparison to structural analyses of  
278 *Sp*PBP2x, is entirely consistent with a non-linear PASTA domain arrangement. First, the  
279 structures of *Sa*PASTA<sub>PBP1</sub> and the PASTA domains of *Sp*PBP2x share a pairwise RMSD of  
280 2.2 Å over 114 C $\alpha$  and when *Sa*PASTA<sub>PBP1</sub> is superimposed on the PASTA domains of  
281 *Sp*PBP2x there are no steric clashes with the TP domain. Second, the linker between PASTAs  
282 in *Sa*PASTA<sub>PBP1</sub> has a sequence of DGDLTMPDMSGW, is neither glycine- nor alanine-rich,  
283 is not predicted to be disordered using IUPred2 or ANCHOR2 webservers and has a mean B  
284 factor of 44 Å<sup>2</sup> in comparison to a mean B factor of 42 Å<sup>2</sup> for the entire chain. Third, the  
285 interface between the PASTA domains is more reminiscent of the hydrophobic core of a  
286 globular protein than the more polar interface observed between molecules in crystal packing.  
287 It would therefore seem unlikely that the two PASTA domains open and close in a hinged  
288 manner, akin to the movement of a butterfly's wings, in the presence and absence of  
289 endogenous PG. Finally, the two proline residues that apparently define PBP1 as a non-binder  
290 of PG are found buried from solvent either at the interface of PASTA domain 1 with the TP  
291 domain (Pro603) or at the interface between the TP domain and PASTA domains 1 and 2

292 (Pro661). This latter interface includes the only tryptophan (Trp666) in the sequence of  
293 *SaPASTA<sub>PBP1</sub>*; tryptophan residues are frequent ‘markers’ of carbohydrate binding sites in  
294 proteins (Hudson et al., 2015) and in the absence of any obvious grooves or surface features  
295 associated with conserved sequence distributions and/or electrostatics it remains unclear how  
296 the PASTA domains of *SaPBP1* recognise PG.

297

## 298 **Discussion**

299 *S. aureus* has just two essential PBPs (Reed et al., 2015) and so forms an apparently simple  
300 system to understand cell wall growth and division. Even the transpeptidase activity of these  
301 two enzymes can be substituted by a single enzyme in the presence of  $\beta$ -lactam antibiotics  
302 via the acquisition of PBP2A, encoded by *mecA*, in MRSA strains. Our recent study has  
303 revealed that the presence of *mecA* and associated genetic lesions have a profound effect on  
304 *S. aureus*, even in the absence of antibiotics (Panchal et al., 2020), leading to the discovery  
305 herein that the PG biosynthetic activity of PBP1 is essential in MSSA but not in MRSA (Fig.  
306 1d). This observation has important ramifications for many studies in *S. aureus* where the use  
307 of an MRSA background can complicate phenotype interpretation. To understand the  
308 fundamental role of PBP1 activity in basic cell physiology we have thus used a MSSA strain  
309 with a defined genetic background.

310

311 The essential function of PBP1 is associated with its crucial role in septal PG synthesis  
312 (Pereira et al., 2009; Reichmann et al., 2019). Here we show that PBP1 is a multifunction  
313 regulatory and PG synthetic protein involved in both early and later stages of septum  
314 synthesis. PBP1 can interact with other cell division components, make and bind to PG. PG  
315 binding is primarily mediated by the PASTA domains that are essential for cell division.  
316 There is clear overall structural similarity between *S. aureus* PBP1 and *S. pneumoniae* PBP2x

317 PASTA domains in the way that the two tandem PASTA domains associate into an anti-  
318 parallel bundle (Fig. 5c); this is in marked contrast to the head-to-tail linear PASTA domain  
319 repeats more typically found in STPKs. The highly hydrophobic interface between the two  
320 PASTA domains means it is unlikely to open up like butterfly wings to bind to PG; similarly  
321 an extensive, linear interaction with PG, which is likely to occur with the head-to-tail PASTA  
322 domain arrangements seen in STPKs and that may require their dimerization (Barthe et al.,  
323 2010), does not occur in *Sa*PBP1. Despite the successful production of diffracting crystals of  
324 *Sa*PASTA<sub>PBP1</sub> grown in the presence of PG fragments (including an *N*-acetylglucosamine:*N*-  
325 acetylmuramic acid disaccharide) none of the structures yielded electron density features  
326 consistent with the stable binding of PG fragments. There are several potential explanations,  
327 including a lack of affinity of PASTA domains for small PG fragments, unrepresentative of  
328 the sacculus of *S. aureus*; our sedimentation assay does not permit the analysis of the binding  
329 of PASTA domains to small, soluble PG precursors. Consequently, and in common with all  
330 other PASTA domain structural analyses, the molecular details of PG recognition by *Sa*PBP1  
331 remain elusive.

332

333 *S. aureus* is a spheroid coccus that can divide successively in three orthogonal planes  
334 (Saraiva et al., 2020; Turner et al., 2010). Septation is first observed as the formation of a  
335 thick band of PG known as the piecrust (Turner et al., 2010). This then transitions to the  
336 production of the septal plate itself, an initially V-shaped structure with a narrower leading  
337 edge (Lund et al., 2018). After closure of the septal annulus, the now bowed septum fills out  
338 to yield the mature structure prior to septal scission. The septal plate has two distinct PG  
339 architectures with a ring-like pattern at its core, which is exposed upon scission, and a  
340 subsequently-synthesised fine mesh, akin to the rest of the peripheral cell wall (Pasquina-  
341 Lemonche et al., 2020). Loss of the entire PBP1, or just its PASTA domains, does not

342 prevent piecrust formation but does result in multi- and/or off-centre piecrusts without the  
343 ability to produce the septal plate (Fig 2f). Thus, piecrust formation does not require PBP1  
344 but is likely the result of the activity of the essential PBP2. PBP1 may regulate division site  
345 selection through PG cell wall recognition via its PASTA domains. Alternatively, as the  
346 division apparatus is unable to progress effectively to septal plate formation due to the lack of  
347 PBP1, this may lead to further rounds of initiation and piecrust formation. PBP1 has a clear  
348 role in septal plate formation where in the absence of PBP1 or the PASTA domains, cells  
349 form aberrantly shaped septa that do not close their annuli (Fig. 2a-e). In stark contrast,  
350 inactivation of PBP1 TP activity (*pbp1\**) does not stop inward septum progression as  
351 observed with loss of PBP1 or the PASTA domains, however, such septa are mis-shapen,  
352 curved and abnormally thick (Fig. 2a-e and Fig. 3). The use of the PBP1-specific antibiotic  
353 MEM at 1x MIC led to the similar morphology of thickened and mis-shapen septa. Two  
354 independent avenues of research both lead to the conclusion that PBP1 TP activity is  
355 essential and, whilst septum formation is disturbed, it is not entirely prevented. Therefore  
356 PBP1 retains its regulatory function(s) regardless of activity loss. As well as binding to the  
357 cell wall, PBP1 also interacts with multiple protein partners including EzrA, DivIB/C, PBP2  
358 and FtsW (Fig. 5 – figure supplement 1a, b) (Steele et al., 2011; Reichmann et al., 2019).  
359 Recently, the PASTA domains from *B. subtilis* PBP2B were shown to regulate PBP2B  
360 interaction with DivIB (Morales Angeles et al., 2020). *S. aureus* DivIB is a PG binding  
361 protein essential for division, which depletion leads to septal plate formation loss (Bottomley  
362 et al., 2014; Steele et al., 2011). Here the PBP1 PASTA domains were found to bind DivIB  
363 and FtsW, alluding to their essential role in cell division. FtsW is a SEDS protein, whose TG  
364 activity requires the presence of PBP1 (Taguchi et al., 2019). Bifunctional aPBPs (including  
365 PBP2) and bPBP-SEDS (including PBP1-FtsW) pairs share similar activities but the fact they  
366 coexist in many bacterial species implies there is a division of responsibilities between them.

367 Indeed, it has been proposed lately that bPBP-SEDS pairs likely lay the primary PG matrix,  
368 while aPBPs support the initial PG by modifying, filling in and adding PG to it (Cho et al.,  
369 2016; Straume et al., 2020). The *S. aureus* septal plate PG has two distinct architectures, a  
370 disordered mesh present on its cytoplasm facing side and a ring structure at its core, which is  
371 revealed after the cells have split (Pasquina-Lemonche et al., 2020; Turner et al., 2010) (Fig.  
372 5 – figure supplement 2). Recent AFM analysis from *Staphylococcus warneri* also describes  
373 the distinct PG architectures during septation as piecrust and septal plate rings/mesh (Su et  
374 al., 2020) . When sacculi are purified from *S. warneri*, the septum can split apart revealing  
375 the rings, even in septa that have not closed their annulus, showing that the rings are not a  
376 result of PG hydrolysis during cell scission. We hypothesise (Fig. 5 – figure supplement 2)  
377 that once the piecrust has been produced, PBP1 and FtsW use this as a foundation to initiate  
378 septal plate formation. Together they make the rings of material that become the core of the  
379 developing septum, providing the framework for PBP2 to make the bulk of the septal plate as  
380 a tight mesh alongside PBP4 and the insertion of WTA via the *tar* pathway. Loss of PBP1 TP  
381 activity in the presence of active PBP2 leads to the lack of the ring framework and aberrant,  
382 unproductive septum formation. The rings that form the centre of the developing septum also  
383 provide the cleavage plane during scission.

384

385 Cell division is a fundamental requirement for life. A central question to this in bacteria is how  
386 is the division septum synthesised and then split to yield two daughter cells whilst maintaining  
387 cellular integrity in the face of internal turgor? Here we have begun to answer this question by  
388 revealing the complex synthesis coordination mechanisms that allow this biological  
389 engineering feat to be accomplished.



## 390 **Materials and methods**

### 391 **Bacterial growth conditions**

392 Strains used in this study are listed in Appendix Table 1.

393 All *Staphylococcus aureus* strains were grown in tryptic soy broth (TSB) containing  
394 appropriate antibiotics at 37°C, unless otherwise indicated, with aeration.

395 All *Escherichia coli* strains, unless otherwise stated, were grown in Lysogeny broth (LB)  
396 containing appropriate antibiotics at temperatures ranging from 20°C to 37°C with aeration.  
397 For solid media 1.5% (w/v) agar was added.

398 When necessary, growth medium was supplemented with kanamycin (50 µg ml<sup>-1</sup>),  
399 tetracycline (1 µg ml<sup>-1</sup>), chloramphenicol (10 µg ml<sup>-1</sup>, *S. aureus*; 30 µg ml<sup>-1</sup>, *E. coli*),  
400 erythromycin (5 µg ml<sup>-1</sup>), spectinomycin (250 µg ml ml<sup>-1</sup>), ampicillin (100 µg ml<sup>-1</sup>),  
401 meropenem (0.4 µg ml<sup>-1</sup>, 1x MIC for SH1000 WT; 0.2 µg ml<sup>-1</sup>, 1x MIC for *pbp3 pbp4*), 5-  
402 bromo-4-chloro-3-indolyl β-d-thiogalactopyranoside (X-Gal; 80 µg ml<sup>-1</sup>, *S. aureus*;  
403 40 µg ml<sup>-1</sup>, *E. coli*) or isopropyl β-d-thiogalactopyranoside (IPTG, 50 µM or 1 mM).

404

### 405 **Plasmid construction**

406 Plasmids and oligos used in this study are listed in Appendix Table 2 and Appendix Table 3,  
407 respectively.

408 Plasmids were cloned using *E. coli* NEB5α following previously described methods (Gibson  
409 et al., 2009; Sambrook et al., 1989).

410

### 411 **pKB-Pspac-pbp1**

412 A fragment containing RBS and coding region of *S. aureus pbp1* was PCR amplified from  
413 the genomic DNA of *S. aureus* SH1000 using pCQ-pbp1-F/-R primers and cloned into NheI  
414 and AscI cut pCQ11-FtsZ-SNAP by Gibson assembly, resulting in pCQ11-Pspac-pbp1. Next

415 the region containing *Pspac*, RBS and *pbp1* was PCR amplified from pCQ11-*Pspac-pbp1*  
416 using pKB-*Pspac-pbp1*-F/-R primers and cloned into BamHI and EcoRI cut pKASBAR by  
417 Gibson assembly giving pKB-*Pspac-pbp1*.

418

#### 419 **pMAD- $\Delta$ *pbp1***

420 Fragments encompassing 1 kb regions flanking upstream (from -980 bp upstream of *pbp1* to  
421 first 20 bp of *pbp1*) and downstream of (from 2214 bp of *pbp1* to 970 bp downstream of  
422 *pbp1*) *pbp1* were PCR amplified from *S. aureus* SH1000 genomic DNA using primer pairs  
423 *pbp1*-A/-B and *pbp1*-C/-D, respectively, and cloned into BamHI and EcoRI cut pMAD by  
424 Gibson assembly, creating a deletion vector pMAD- $\Delta$ *pbp1*.

425

#### 426 **pMAD-*pbp1* $\Delta$ PASTA**

427 Fragments encompassing 1.5 kb regions flanking the region encoding *pbp1* PASTA domains  
428 (upstream, from 286 bp to 1785 bp of *pbp1*; downstream, from 2214 bp of *pbp1* to 970 bp  
429 downstream of *pbp1*) were PCR amplified from *S. aureus* SH1000 genomic DNA using  
430 *pbp1*-E/-F and *pbp1*-G/-H primers and cloned into BamHI and EcoRI cut pMAD by Gibson  
431 assembly, resulting in a deletion vector pMAD-*pbp1* $\Delta$ PASTA.

432

#### 433 **pMAD-*pbp1*\***

434 A ~1.3 kb fragment covering an upstream region of the active site of *pbp1* (from -334 bp  
435 upstream of *pbp1* to first 950 bp of the *pbp1* coding sequence), and a ~1.3 kb fragment  
436 comprising the 3' fragment of *pbp1* (930-2235 bp region of *pbp1*) were PCR amplified from  
437 *S. aureus* SH1000 genomic DNA using primer pairs *pbp1*\*5'-F/-R and *pbp1*\*3'-F/-R,  
438 respectively. Primers *pbp1*\*5'-R and *pbp1*\*3'-F were designed to introduce a T to G point

439 mutation resulting in a Ser314Ala substitution. The PCR products were ligated with pMAD  
440 cut with EcoRI and BamHI by Gibson assembly, resulting in pMAD-*pbp1*\*.

441

#### 442 **T25-PBP1 $\Delta$ PASTA**

443 A fragment encoding *S. aureus pbp1* without the PASTA domains (M1-S595) was PCR  
444 amplified from *S. aureus* SH1000 genomic DNA using T25-pbp1-F and T25-pbp1pasta-R  
445 and cloned into BamHI and EcoRI cut pKT25, resulting in T25-PBP1 $\Delta$ PASTA.

446

#### 447 **pVR plasmids**

448 Full-length *pbp1* (M1-D744) was *E. coli* codon optimised, synthesised by GenScript, PCR  
449 amplified using VR47F/R and cloned into KpnI and HindIII cut pOPINRSF using In-Fusion  
450 cloning (Takara Bio), resulting in pVR01. Construction of pVR02 (*Sa*PBP1, M37-D744) and  
451 pVR06 (*Sa*PASTA<sub>PBP1</sub>, S595-D744) was performed using inverse PCR (iPCR) (Erster &  
452 Liscovitch, 2010), pVR01 as a template and primer pairs VR49F/VR49R and  
453 VR57F/VR49R, respectively. pVR03 (*Sa*PBP1\*, M37-D744, S314A) and pVR04  
454 (*Sa*PBP1 $\Delta$ PASTA, M37-S595), were constructed by QuikChange Site-Directed Mutagenesis of  
455 pVR02 using VR51 and VR53, respectively.

456

#### 457 **pSA50**

458 In order to construct an overexpression plasmid for sPBP1-BAP, A51-D744 fragment of *E.*  
459 *coli* codon optimised *pbp1* was PCR amplified using primers OPPF20018F/OPPF20018R  
460 and cloned into KpnI and SfoI cut pOPINJB by In-Fusion cloning (Takara Bio). The resulting  
461 construct, pSA50 contains an N-terminal hexahistidine-tag fused to Glutathione-S-transferase  
462 followed by a Human Rhinovirus 3C protease site, while the PBP1 (A51-D744) C-terminal  
463 end is fused to a Biotin Acceptor Peptide (BAP) sequence.

464

## 465 **Construction of *S. aureus* mutants**

466 All vectors were passed through a restriction-deficient *S. aureus* RN4220 before being  
467 transduced into a final *S. aureus* SH1000 strain. Transformation and phage transduction of *S.*  
468 *aureus* were carried out as described previously (Novick & Morse, 1967; Schenk & Laddaga,  
469 1992).

470

### 471 ***Δpbp1*, *pbp1*<sub>ΔPASTA</sub> and *pbp1*\***

472 For construction of *pbp1* mutation strains, first an ectopic copy of *pbp1* under the control of  
473 the *Pspac* promoter was introduced at the lipase (*geh*) locus. Electrocompetent CYL316 was  
474 transformed with pKB-*Pspac-pbp1*. The chromosomal fragment containing the integrated  
475 plasmid was moved into *S. aureus* SH1000 by phage transduction, resulting in SJF4588 (*S.*  
476 *aureus* SH1000 *geh::Pspac-pbp1*). Next electrocompetent RN4220 was transformed with  
477 pMAD-*Δpbp1*, pMAD-*pbp1*<sub>ΔPASTA</sub> or pMAD-*pbp1*\* and the plasmids were moved to  
478 SJF4588 by phage transduction. Integration at 42°C and excision at 28°C of pMAD-*Δpbp1*,  
479 pMAD-*pbp1*<sub>ΔPASTA</sub> or pMAD-*pbp1*\*, resulted in strains SJF5116, SJF5275 and SJF4590,  
480 respectively. To allow controlled expression of *pbp1* from *Pspac*, pGL485, a multi-copy  
481 plasmid carrying *lacI*, was introduced creating strains *Δpbp1* (*S. aureus* SH1000 *geh::Pspac-*  
482 *pbp1 Δpbp1 lacI*), *pbp1*<sub>ΔPASTA</sub> (*S. aureus* SH1000 *geh::Pspac-pbp1 pbp1*<sub>ΔPASTA</sub> *lacI*) and  
483 *pbp1*\* (*S. aureus* SH1000 *geh::Pspac-pbp1 pbp1*\* *lacI*).

484

### 485 **MRSA *Δpbp1* and MRSA *pbp1*\***

486 In order to construct high-level β-lactam resistant mutants, *Δpbp1* and *pbp1*\* were  
487 transformed with a phage lysate from SJF5046 (*S. aureus* SH1000 *lysA::pmecA rpoB*<sup>H929Q</sup>)  
488 with selection for erythromycin resistance, resulting in low-level β-lactam resistant *Δpbp1*

489 *pmecA* and *pbp1\** *pmecA*. The low-level resistant mutants were transduced again with the  
490 phage lysate from SJF5046 and selected for kanamycin resistance, resulting in MRSA  $\Delta$ *pbp1*  
491 (*S. aureus* SH1000 *geh::Pspac-pbp1*  $\Delta$ *pbp1 lacI lysA::pmecA rpoB<sup>H929Q</sup>*) and MRSA *pbp1\**  
492 *pbp1* (*S. aureus* SH1000 *geh::Pspac-pbp1 pbp1\* lacI lysA::pmecA rpoB<sup>H929Q</sup>*). MIC values  
493 were determined using antibiotic susceptibility tests using E-test M.I.C. Evaluator (Oxoid)  
494 strips.

495

#### 496 ***pbp3 pbp4***

497 SH1000 was transduced with a phage lysate from NE420 (*S. aureus* JE2 *pbp3::Tn*) resulting  
498 in SH4421 (*S. aureus* SH1000 *pbp3::Tn*). To swap the erythromycin resistance cassette to a  
499 kanamycin cassette, SH4425 (*S. aureus* SH1000 *pbp4::Tn*) was transduced with a phage  
500 lysate from NE3004 (*S. aureus* RN4220 pKAN). Integration at 42°C and excision at 28°C of  
501 pSPC resulted in strain SH5115 (*S. aureus* SH1000 *pbp4::kan*). SH4421 was subsequently  
502 transduced with a phage lysate from SH5115 (*S. aureus* SH1000 *pbp4::Tn*) resulting in *pbp3*  
503 *pbp4* (SH5483; *S. aureus* SH1000 *pbp3::Tn pbp4::kan*).

504

#### 505 **$\Delta$ *pbp1 pbp4*, *pbp1* <sub>$\Delta$ PASTA</sub> *pbp4* and *pbp1\** *pbp4***

506  $\Delta$ *pbp1*, *pbp1* <sub>$\Delta$ PASTA</sub> and *pbp1\** were transduced with a phage lysate from SH5115 (*S. aureus*  
507 SH1000 *pbp4::kan*), resulting in  $\Delta$ *pbp1 pbp4* (*S. aureus* SH1000 *geh::Pspac-pbp1*  $\Delta$ *pbp1*  
508 *lacI pbp4::kan*), *pbp1* <sub>$\Delta$ PASTA</sub> *pbp4* (*S. aureus* SH1000 *geh::Pspac-pbp1 pbp1* <sub>$\Delta$ PASTA</sub> *lacI*  
509 *pbp4::kan*) and *pbp1\** *pbp4* (*S. aureus* SH1000 *geh::Pspac-pbp1 pbp1\* lacI pbp4::kan*),  
510 respectively.

511

#### 512 ***pbp1\** *pbp3 pbp4***

513 *pbp1\* pbp4* (*S. aureus* SH1000 *geh::Pspac-pbp1 pbp1\* lacI pbp4::kan*) was transduced with  
514 a phage lysate from SH4421 (*S. aureus* SH1000 *pbp3::Tn*), resulting in *pbp1\* pbp3 pbp4* (*S.*  
515 *aureus* SH1000 *geh::Pspac-pbp1 pbp1\* lacI pbp3::Tn pbp4::kan*).

516

#### 517 ***Δpbp1 ezrA-gfp, pbp1<sub>ΔPASTA</sub> ezrA-gfp* and *pbp1\* ezrA-gfp***

518 *Δpbp1, pbp1<sub>ΔPASTA</sub>* and *pbp1\** were transduced with a phage lysate from JGL227 (*S. aureus*  
519 SH1000 *ezrA-gfp<sup>+</sup>*), resulting in *Δpbp1 ezrA-gfp* (*S. aureus* SH1000 *geh::Pspac-pbp1 Δpbp1*  
520 *lacI ezrA-gfp*), *pbp1<sub>ΔPASTA</sub> ezrA-gfp<sub>PASTA</sub>* (*S. aureus* SH1000 *geh::Pspac-pbp1 pbp1<sub>ΔPASTA</sub>*  
521 *lacI ezrA-gfp*) and *pbp1\* ezrA-gfp* (*S. aureus* SH1000 *geh::Pspac-pbp1 pbp1\* lacI ezrA-gfp*),  
522 respectively.

523

#### 524 ***Δpbp1 tarO, pbp1<sub>ΔPASTA</sub> tarO* and *pbp1\* tarO***

525 *Δpbp1, pbp1<sub>ΔPASTA</sub>* and *pbp1\** were transduced with a phage lysate from *tarO tarO<sup>+</sup>* (*S.*  
526 *aureus* SA113 *ΔtarO::ery pUC1-tarO*), resulting in *Δpbp1 tarO* (*S. aureus* SH1000  
527 *geh::Pspac-pbp1 Δpbp1 lacI ΔtarO::ery*), *pbp1<sub>ΔPASTA</sub> tarO<sub>PASTA</sub>* (*S. aureus* SH1000  
528 *geh::Pspac-pbp1 pbp1<sub>ΔPASTA</sub> lacI ΔtarO::ery*) and *pbp1\* tarO* (*S. aureus* SH1000  
529 *geh::Pspac-pbp1 pbp1\* lacI ΔtarO::ery*), respectively.

530

#### 531 **PBP1 depletion**

532 *Pspac-pbp1* strains were grown from an OD<sub>600</sub> of 0.1 to exponential phase (OD<sub>600</sub> ~ 0.5) in  
533 TSB containing 10 μg ml<sup>-1</sup> chloramphenicol and 50 μM IPTG. Cells were washed three  
534 times by centrifugation and resuspension in TSB. Washed cells were then used to inoculate  
535 TSB 10 μg ml<sup>-1</sup> chloramphenicol. Cultures were inoculated to an OD<sub>600</sub> 0.05 for phenotypic  
536 studies and an OD<sub>600</sub> 0.005 for growth studies. For phenotypic analysis, cultures were  
537 incubated for 2 h to allow depletion of PBP1 before microscopy imaging. Control samples

538 were grown in TSB supplemented with 10  $\mu\text{g ml}^{-1}$  chloramphenicol and 1 mM (50  $\mu\text{M}$ , *ezrA-*  
539 *gfp* mutants) IPTG.

540 For the plating efficiency test, cells grown in the presence of 10  $\mu\text{g ml}^{-1}$  chloramphenicol and  
541 50  $\mu\text{M}$  IPTG to exponential phase ( $\text{OD}_{600} \sim 0.5$ ) were washed three times in PBS. Serial  
542 dilutions of washed cells were plated on TSB 10  $\mu\text{g ml}^{-1}$  chloramphenicol with or without 1  
543 mM IPTG. Relative plating efficiency (%CFU) is expressed as the number of cells that grow  
544 on plates without IPTG ( $\text{CFU}_{no\ IPTG}$ ) to cells that grow in the presence of IPTG ( $\text{CFU}_{IPTG}$ )  
545 multiplied by 100%:

$$546 \quad \%CFU = \frac{\text{CFU}_{no\ IPTG}}{\text{CFU}_{IPTG}} \times 100\%$$

547

#### 548 **Meropenem activity assays**

549 *S. aureus* strains were grown overnight in TSB. The overnight cultures were used to inoculate  
550 fresh TSB media to an  $\text{OD}_{600}$  of 0.05. When cells reached an  $\text{OD}_{600}$  of 0.2-0.4, meropenem  
551 was added, and the change of bacterial count was monitored. The colony-forming units per  
552 ml of culture (CFU/ml) measures were normalized to the initial CFU/ml at the time of the  
553 antibiotic addition, at time zero ( $t_0$ ).

$$554 \quad \text{Relative CFU/ml} = \frac{\text{CFU/ml}_{t_n}}{\text{CFU/ml}_{t_0}}$$

555 For phenotypic analysis, cells were treated for 1 h with 1x MIC meropenem before  
556 microscopy imaging.

557

#### 558 **Fractionation of *S. aureus* membranes**

559 The membrane fraction of *S. aureus* was prepared as previously described (García-Lara et al.,  
560 2015) with the following modifications. *S. aureus* cells grown to the appropriate growth  
561 phase were recovered by centrifugation (5,000  $\times$  g, 10 min, 4°C), washed three times by

562 resuspension and centrifugation (5,000 x g, 10 min, 4°C) in PBS. Cells were resuspended in  
563 TBSI and broken using 0.1 mm silica spheres (Lysing Matrix B) and FastPrep Homogenizer  
564 (MP Biomedicals) in 12 cycles of 30 s, at maximum speed (6.5 m s<sup>-1</sup>), with 5 min incubation  
565 on ice between cycles. Cell lysates were centrifuged (5,000 x g, 10 min, 4°C) to remove  
566 unbroken cells. The supernatant was then spun (5,000 x g, 10 min, 4°C) to sediment cell wall  
567 material. The membrane fraction was recovered from the supernatant by centrifugation  
568 (35,000 x g, 20 min, 4°C) and the pellet (membranes) was resuspended in PBS. The total  
569 protein concentration was estimated by Bradford assay.

570

#### 571 ***In vitro* labelling of *S. aureus* PBPs with BocillinFL**

572 This method was adopted from a published protocol (Zhao et al., 1999) with minor  
573 modifications. Membrane proteome samples (25 µg in 20 µl PBS) and purified proteins (2.5  
574 µg in 25 µl HEPES pH 7.5 150 mM NaCl) were incubated with 25 µM BocillinFL  
575 (Invitrogen) for 20 min at 37°C. Additionally for competition assay, purified SaPBP1 was  
576 mixed with 2.5 µg (~286 µM final concentration) ampicillin and incubated at 37°C for 10  
577 min prior to the addition of BocillinFL. The reaction was stopped by the addition of 5x SDS-  
578 PAGE loading buffer. Membrane proteome was additionally incubated for 10 min at 90°C.  
579 The samples were run on a 6-20% (w/v) SDS-PAGE gradient or 10% (w/v) SDS-PAGE gel  
580 and visualized using a BioRad ChemiDoc MP Imaging system or a GE Typhoon FLA 9500.

581

#### 582 **Labelling *S. aureus* DAAs**

583 *S. aureus* cells were incubated with 500 µM (2 mM for *pbp4* mutants) HADA or 1 mM  
584 ADA-DA at 37°C for 5 min. Cells were then washed by centrifugation and resuspension in  
585 PBS.

586



587 **Click chemistry**

588 ADA-DA containing an azide functional group was fluorescently labelled with Alexa Fluor  
589 488 Alkyne at 5  $\mu\text{g ml}^{-1}$  via the Click reaction (copper (I)-catalysed alkyne-azide  
590 cycloaddition). This was carried out using the Click-iT Cell Reaction Buffer Kit  
591 (ThermoFisher) according to the manufacturer's protocol.

592

593 **Labelling *S. aureus* with fluorescent NHS-ester**

594 Fixed cells wells were resuspended in PBS containing 8  $\mu\text{g ml}^{-1}$  Alexa Fluor 555 NHS ester  
595 (Invitrogen) and incubated at room temperature for 30 min. Cells were washed twice by  
596 centrifugation and resuspension in PBS.

597

598 **Fixing for fluorescence microscopy**

599 Cells were fixed by incubation in 1.6% (w/v) paraformaldehyde at room temperature for 30  
600 min.

601

602 **Fluorescence microscopy**

603 Fixed cells were dried onto a poly-L-Lysine coated slide, mounted in PBPS and imaged on a  
604 Nikon Ti Inverted microscope fitted with a Lumencor Spectra X light engine. Images were  
605 taken using a 100x PlanApo (1.4 NA) oil objective using 1.518 RI oil and detected by an  
606 Andor Zyla sCMOS camera.

607

608 **Cell volume estimation**

609 Cell volume calculations were carried out as previously described (Zhou et al., 2015). The  
610 long and short axis of cells were measured using Fiji. The volume was then calculated based  
611 on a prolate spheroid shape with volume:

612 
$$V = \frac{4}{3}\pi ab^2,$$

613 where  $a$  and  $b$  are the radii along the long and short axis, respectively.

614

### 615 **Transmission electron microscopy**

616 *S. aureus* strains were prepared for electron microscopy as previously described (Sutton et  
617 al., 2021).

618

### 619 **Preparation of *S. aureus* sacculi**

620 Peptidoglycan from *S. aureus* cells was extracted and if required HF treated to remove cell  
621 wall polymers as previously described (Sutton et al., 2021).

622

### 623 **Sacculi immobilisation for AFM Imaging**

624 Immobilisation surface was prepared by adding the solution mixed by 171  $\mu$ L 100 mM  
625  $\text{NaHCO}_3$ , 3  $\mu$ l of 1 M NaOH and 6  $\mu$ l of Cell-Tak (Corning, 5% (w/v) in acetic acid) on  
626 freshly cleaved mica. After 30 min incubation, the surface was washed by  $5 \times 200$   $\mu$ l HPLC  
627 grade water. Sacculi stocks were 10 times diluted in HPLC grade water and briefly tip-  
628 sonicated to re-suspend in prior to immobilisation. 10  $\mu$ l of the sacculi suspension was added  
629 to 40  $\mu$ l of HPLC grade water on the Cell-Tak immobilisation surface and incubated for 1 h.  
630 The surface was then thoroughly rinsed with HPLC grade water, blow-dried with nitrogen  
631 and stored in petri-dish at room temperature before AFM imaging.

632

### 633 **AFM Imaging and image analysis**

634 AFM imaging was carried out on a Nanowizard III ULTRA Speed system (JPK, Germany).  
635 Rectangular cantilevers with nominal spring constant of 0.3 N/m and resonant frequency (in  
636 liquid) of  $\sim 150$  kHz (USC-F0.3-k0.3, NanoWorld, Switzerland) were used. The spring

637 constant and deflection sensitivity of each cantilever was calibrated prior to each  
638 measurement (Hutter & Bechhoefer, 1993; Sader et al., 2016) Measurements were carried out  
639 in Quantitative Imaging mode at room temperature, in the buffer composed of 200 mM KCl  
640 and 10 mM Tris. Scans were driven at a line rate of ~ 0.78 Hz, with a typical Z length of 300  
641 nm and trigger force of 20 nN.

642 Resultant topographic images were processed using JPK Data Processing. No flattening or  
643 surface subtraction was applied. High pass filter (scale: 100% to 500%, degree of smoothing:  
644 5 px, horizontal) was applied to the higher magnification images to enhance the contrast  
645 without modifying the morphological features. The morphological features of sacculi were  
646 summarised from images obtained on abundant technical repeats of 2 biological replicates.

647

## 648 **Recombinant protein production and purification**

### 649 **sPBP1-BAP**

650 *E. coli* BL21(DE3) cells containing plasmid pSA50 were grown in LB medium supplemented  
651 with 100 µg ml<sup>-1</sup> ampicillin at 37°C to an OD<sub>578</sub> of 0.5. Protein overproduction was induced  
652 by addition of 0.5 mM IPTG to the cell culture and further incubation for 4 h at 30°C. Cells  
653 were harvested by centrifugation (6,200 x g, 15 min, 4°C) and the pellet was resuspended in  
654 basic buffer (25 mM Tris-HCl, 100 mM NaCl, pH 7.5). After addition of 1 mM PMSF,  
655 1:1,000 dilution of protease inhibitor cocktail (Sigma-Aldrich) and DNase, the cells were  
656 disrupted by sonication (Branson Digital Sonifier). The cell lysate was centrifuged (130,000  
657 x g, 60 min, 4°C) and the supernatant was recovered. The supernatant was incubated with Ni-  
658 NTA Superflow (Qiagen) for 2 h at 4°C with gentle stirring, which had been pre-equilibrated  
659 in basic buffer. The resin was poured into a gravity column and washed with 20 volumes of  
660 wash buffer (25 mM Tris-HCl, 150 mM NaCl, 10% (v/v) glycerol, 10 mM MgCl<sub>2</sub>, 20 mM  
661 imidazole, pH 7.5). Bound protein was eluted with elution buffer (25 mM Tris-HCl, 150 mM

662 NaCl, 10% (v/v) glycerol, 10 mM MgCl<sub>2</sub>, 600 mM imidazole, pH 7.5). 10 U ml<sup>-1</sup> of HRV-  
663 3C protease (Takara) were added to the Ni-NTA eluted protein to remove the oligohistidine-  
664 GST-tag during dialysis against 3 L of dialysis buffer I (25 mM Tris-HCl, 150 mM NaCl, 10  
665 mM EGTA, 10% (v/v) glycerol, pH 7.5) for 20 h at 4°C. Digested protein was dialysed  
666 against 3 L of dialysis buffer II (25 mM Tris-HCl, 150 mM NaCl, 10 mM MgCl<sub>2</sub>, 10% (v/v)  
667 glycerol, pH 7.5), for 3 h at 4°C. The protein was incubated in the same Ni-NTA beads (pre-  
668 equilibrated in dialysis buffer II) for 2 h at 4°C to remove the contaminants and the His-GST  
669 tag from the sample. The flow through and the washes (2 volume of wash buffer) were  
670 pooled, dialysed against storage buffer (25 mM HEPES-NaOH, 150 mM NaCl, 10 mM  
671 MgCl<sub>2</sub>, 10% (v/v) glycerol, pH 7.5) and concentrated using a Vivaspin Turbo 15 column  
672 (MWCO 50000 Da).

673

#### 674 ***SaPBP1*, *SaPBP1\**, *SaPBP1*<sub>ΔPASTA</sub> and *SaPASTA*<sub>PBP1</sub>**

675 All recombinant proteins were produced in *E. coli* Rosetta (DE3) cells at 37°C in TB medium  
676 supplemented with 50 μg ml<sup>-1</sup> kanamycin and 30 μg ml<sup>-1</sup> chloramphenicol. Once cultures had  
677 reached OD<sub>600</sub> 0.9, protein expression was induced with 1 mM IPTG for 20 h at 20°C. Cells  
678 were harvested by centrifugation (4,000 x g at 4°C for 30 mins) and the pellet was  
679 resuspended in a buffer of 50 mM Tris-HCl pH 8.0, 500 mM NaCl, 20 mM imidazole  
680 supplemented with one EDTA-free protease inhibitor cocktail tablet (Roche) and DNase (4  
681 μg ml<sup>-1</sup> final concentration). Cells in this resuspension were lysed by two passes through a  
682 One-Shot cell disruptor (Constant Systems) at 23 kpsi and the cell debris was removed by  
683 centrifugation (40,000 x g at 4°C for 30 min). The first purification step was affinity  
684 chromatography with a 5 mL HisTrap™ FF column (GE Healthcare) precharged with Ni<sup>2+</sup>  
685 and equilibrated in buffer A (50 mM Tris-HCl, pH 8.0, 500 mM NaCl, 20 mM imidazole). A  
686 linear concentration gradient of imidazole was applied to elute the protein using buffer B (50

687 mM Tris-HCl, pH 8.0, 500 mM NaCl, 800 mM imidazole). Further purification was carried  
688 out by size exclusion chromatography using a Superdex™ 200 Hi Load 16/60 column (GE  
689 Healthcare). Proteins were eluted with SEC buffer (25 mM Tris-HCl, pH 8.0, 150mM NaCl)  
690 and analysed by SDS-PAGE.

691

### 692 **Generation of anti-PBP1 antibody**

693 Serum against sPBP1A-BAP was produced from rabbits following a 28-day immunisation  
694 program at Eurogentec (Belgium), and it was purified as previously described (Bertsche et  
695 al., 2006).

696

### 697 **Immunoblot analysis**

698 *S. aureus* cultures were washed three times by resuspension and centrifugation (5,000 x g, 10  
699 min, 4°C) in PBS. Cells were resuspended in TBSI (50 mM Tris, 100 mM NaCl, pH 8, plus  
700 Complete Protease Inhibitor Cocktail, Roche) and broken using 0.1 mm silica spheres  
701 (Lysing Matrix B) and FastPrep Homogenizer (MP Biomedicals) in 12 cycles of 30 s, at  
702 maximum speed (6.5 m s<sup>-1</sup>), with 5 min incubation on ice between cycles. Cell lysates were  
703 centrifuged (5,000 x g, 10 min, 4°C) to remove unbroken cells. ~ 60 µg of total protein was  
704 separated on a 12% (w/v) SDS-PAGE gel and electroblotted onto a nitrocellulose membrane  
705 and blocked in 5% (w/v) skimmed-milk in TBST (20 mM Tris-HCl, pH 7.6; 17 mM NaCl,  
706 0.1% (v/v) Tween-20). The membrane blocked in 5% (w/v) skimmed-milk in TBST (20 mM  
707 Tris-HCl, pH 7.6; 17 mM NaCl, 0.1% (v/v) Tween-20) was incubated with primary  
708 polyclonal anti-PBP1 (1:1,000) overnight with gentle agitation at 4°C. Primary antibodies  
709 were detected using horseradish peroxidase-conjugated goat anti-rabbit IgG (1:10,000,  
710 BioRad) and Clarity Western ECL Substrate (BioRad) reagent according to the

711 manufacturer's protocol. Chemiluminescence was detected using Syngene G:BOX Chemi  
712 XX9.

713

#### 714 **Crystallisation, data collection and structure determination**

715 Crystallisation of *SaPASTA*<sub>PBP1</sub> was carried out at 20°C by the sitting-drop vapour diffusion  
716 method in 96-well MRC plates (Molecular Dimensions) with a Mosquito crystallisation robot  
717 (TTP LabTech) and commercial crystallisation screens (Hampton Research and Molecular  
718 Dimensions). Orthorhombic crystals of diffraction quality, with a maximum dimension of  
719 approximately 500 µm, appeared overnight from a mixture of equal volumes of protein  
720 solution (42 mg ml<sup>-1</sup> in 25 mM Tris-HCl, pH 8.0, 150 mM NaCl) and reservoir solution (0.2  
721 M NaCl, 0.1 M sodium/potassium phosphate pH 6.2, 50 % (v/v) PEG 200). Diffraction data  
722 were indexed and integrated using XDS (Kabsch, 2010) and scaled using AIMLESS (Evans  
723 & Murshudov, 2013) from the CCP4 program suite (Winn et al., 2011). The crystals display  
724 space group *P*2<sub>1</sub>2<sub>1</sub>2<sub>1</sub> with unit cell lengths *a* = 39.8 Å, *b* = 81.4 Å and *c* = 89.6 Å. The  
725 asymmetric unit consists of two polypeptide chains with an estimated solvent content of 45 %  
726 and a *V<sub>m</sub>* of 2.24 Å<sup>3</sup>/Da. The region corresponding to the two PASTA domains in the crystal  
727 structure of *S. pneumoniae* PBP2x (PBP 5OAU) was used as a molecular replacement search  
728 model, sharing approximately 26 % sequence identity with *SaPASTA*<sub>PBP1</sub>. The search model  
729 was generated using phenix.sculptor (Bunkóczi & Read, 2011) to remove non-  
730 macromolecular chains and prune sidechains. The structure was solved by molecular  
731 replacement using PHASER (McCoy et al., 2007) and the resultant electron density map was  
732 of high quality, allowing the tracing of the main chain. Model building and refinement were  
733 carried out with Coot (Emsley et al., 2010) and Phenix (Liebschner et al., 2019), respectively.  
734 Assessments of the geometry and validation of the final model was carried out using  
735 Molprobit (Chen et al., 2010). Analyses of surface areas and interactions were made using

736 the PISA web service (Krissinel & Henrick, 2007). The graphics program PyMOL  
737 (Schrödinger, LLC, 2015) was used to generate all molecular figures presented.

738

### 739 **Cell wall binding assays**

740 Cell wall binding assays of recombinant PBP1 proteins fluorescently labelled with Cy2 bis-  
741 reactive dye (GE Healthcare) were performed as previously described (Bottomley et al.,  
742 2014).

743

### 744 **Bacterial two-hybrid**

745 Competent BTH101 was co-transformed with pKT25 and pUT18 derivatives. Transformants  
746 were selected on LB agar plates containing 100 µg ml<sup>-1</sup> ampicillin, 50 µg ml<sup>-1</sup> kanamycin  
747 and 40 µg ml<sup>-1</sup> X-Gal and incubated at 30°C. Single colonies were grown in 150 µl LB with  
748 100 µg ml<sup>-1</sup> ampicillin, 50 µg ml<sup>-1</sup> kanamycin and 0.5 mM IPTG at 30°C.

749 To qualitatively measure for pairwise interactions, 5 µl of each overnight culture were spotted  
750 onto LB agar plates containing 100 µg ml<sup>-1</sup> ampicillin, 50 µg ml<sup>-1</sup> kanamycin, 0.5 mM IPTG  
751 and 40 µg ml<sup>-1</sup> X-Gal. Plates were incubated at 30°C 24 – 48 h in an environment protected  
752 from light and imaged. To quantify interactions, overnight cultures were assayed for β-  
753 galactosidase activity against MUG (4-methylumbelliferyl-β-d-galactopyranoside) using an  
754 assay as previously described (Steele et al., 2011).

755

### 756 **Acknowledgements**

757 This work was funded by the Medical Research Council (MR/N002679/1; MR/K015753/1),  
758 UKRI Strategic Priorities Fund (EP/T002778/1) and the Wellcome Trust (212197/Z/19/Z).  
759 L.L. thanks The Florey Institute for her PhD studentship. We gratefully acknowledge the  
760 Wolfson Light Microscopy facility for their support and assistance in this work. We thank

761 Diamond Light Source for access to beamline I24 (mx18598) and Arnaud Baslé for data  
762 collection, help with figure generation and support. We are grateful to Joshua Sutton, Grace  
763 Pidwill, Victoria Lund, Laia Pasquina-Lemonche and Christopher Hill for help and advice.

764


### 765 **Competing Interests**

766 The authors declare no competing interests.



767 **Figures and figure legends**

768



769

770 **Fig. 1 Essentiality of PBP1**

771 **a**, Schematic representation of genetic constructs used in this study. In *S. aureus* WT (*wt*) the  
 772 5' end of *pbb1* overlaps with the 3' of *ftsL*. The *pbb1* gene encodes a protein containing the  
 773 transmembrane helix (TM), N-terminal domain (N), transpeptidase (TP) domain and two  
 774 PASTA domains (P1 and P2). In the mutants, an ectopic copy of *pbb1* is placed under the  
 775 control of the *Pspac* promoter at the lipase (*geh*) locus, whereas the gene in the native *pbb1*  
 776 locus is either deleted (*Δpbb1*), has P1 and P2 domains removed (*pbb1<sub>ΔPASTA</sub>*), or has a point  
 777 mutation which results in inactivation of the TP domain (*pbb1\**).

778 **b**, Schematic representation of domain architecture of PBP1 in *S. aureus* WT (*wt*) and PBP1  
 779 forms produced by *Δpbb1*, *pbb1<sub>ΔPASTA</sub>* and *pbb1\** mutants in the absence of inducer. The TP  
 780 domain inactivation is shown by dotted shading.


781 **c**, Immunoblot showing PBP1 levels in SH1000 *lacI* (*wt*) and in *Δpbb1*, *pbb1<sub>ΔPASTA</sub>* and  
 782 *pbb1\** grown with IPTG (+IPTG) and for 0, 1, 2 and 3 h without inducer (-IPTG) analysed  
 783 using anti-PBP1 antibody. Expected sizes: PBP1 and PBP1\* = 83 kDa (black and grey  
 784 arrowheads, respectively) and PBP1<sub>ΔPASTA</sub> = 67 kDa (light blue arrowhead).

785 **d**, Plating efficiency of  $\Delta pbpI$ ,  $pbpI_{\Delta PASTA}$  and  $pbpI^*$  (MSSA) cells and MRSA  $pbpI^*$   
786 ( $pbpI^*_{MRSA}$ ) cells upon inducer removal compared to the control groups grow in the presence  
787 of inducer.  $P$  value was determined by Mann–Whitney  $U$  tests.  $P = 0.0043$  (\*\*,  $P < 0.01$ ).  
788 Data represent mean  $\pm$  SD.

789 **e**, Growth curves of  $pbpI^*$  (MSSA) and MRSA  $pbpI^*(pbpI^*_{MRSA})$  in the presence (+) or  
790 absence (-) of IPTG. Data represent mean  $\pm$  SD. Error bars that are smaller than the symbols  
791 are not shown.

792

793 Data are representative of three (c, e) and at least four (d) independent experiments.



794

795 **Fig. 2 The role of PBP1 in cell division and PG synthesis in *S. aureus*.**

796 **a**,  $\Delta pbb1$ ,  $pbb1_{\Delta PASTA}$  and  $pbb1^*$  grown with or without IPTG for 2 h, incubated with HADA  
 797 for 5 min to show nascent PG, and counter-labelled with NHS-ester Alexa Fluor 555 to  
 798 image the cell wall. Images are average intensity projections of *z* stacks. Scale bars 2  $\mu$ m.

799 **b**, Cell volumes of WT (*wt*),  $\Delta pbb1$ ,  $pbb1_{\Delta PASTA}$  and  $pbb1^*$  grown with (+) or without (-)  
 800 IPTG for 2 h as measured by fluorescence microscopy after NHS-ester Alexa Fluor 555  
 801 labelling. Each dot represents a single cell. The median of each distribution is indicated by a  
 802 black line. The number of cells analysed for each mutant and condition was  $n \geq 100$ . *P* value  
 803 was determined by Mann–Whitney *U* tests (\*\*\*\*,  $P < 0.0001$ ). From left to right:  $P = 3.033e$ -  
 804  $033$ ,  $4.670e-049$  and  $2.206e-022$ ;  $n = 100, 101, 100, 101, 100, 100$  and  $101$ .

805 **c**, Quantification of cellular phenotypes for WT (*wt*),  $\Delta$ *pbp1*, *pbp1* $_{\Delta$ PASTA and *pbp1*\* based on  
806 HADA incorporation (Fig. 2a) after incubation with (+) or without (-) IPTG for 2 h. From left  
807 to right  $n = 370, 427, 332, 314, 364, 512$  and 331.


808 **d**, TEM of  $\Delta$ *pbp1*, *pbp1* $_{\Delta$ PASTA and *pbp1*\* grown for 2 h in the absence of inducer. Scale bars  
809 500 nm.

810 **e**, Quantification of cellular phenotypes based on TEM data of  $\Delta$ *pbp1*, *pbp1* $_{\Delta$ PASTA and *pbp1*\*  
811 grown for 2 h in the presence (+) or absence (-) of IPTG. Examples of cells classified as  
812 normal (blue) are shown in Fig. 2 – figure supplement 2b. Cells with abnormal phenotypes  
813 (light blue) are shown in Fig. 2d and Fig. 2 – figure supplement 2c. From left to right  $n =$   
814 391, 329, 314, 377, 263 and 302.

815 **f**, AFM topographic images of internal surface of purified sacculi from  $\Delta$ *pbp1*, *pbp1* $_{\Delta$ PASTA  
816 and *pbp1*\* grown in the absence of inducer for 2 h. Sacculi (top images, scale bars 500 nm,  
817 data scales ( $z$ ): 450, 300 and 100 nm from left to right, respectively) and higher magnification  
818 images (bottom images, scale bars 50 nm, data scales ( $z$ ): 70, 100 and 50 nm from left to right  
819 respectively) scanned within the boxed areas from the top images.

820

821 Data are representative of two (d-f) and (a-c) three independent experiments.



822

823 **Fig. 3 Effect of meropenem (MEM), an antibiotic with high affinity for PBP1, on *S.***

824 ***aureus*.**

825 **a**, Fluorescence images of SH1000 WT treated with 1x MIC MEM for 1 h, labelled with  
826 HADA for 5 min to show nascent PG and counter labelled with NHS-ester Alexa Fluor 555  
827 (cell wall). Images are average intensity projections of z stacks. Scale bars 2 μm.

828 **b**, Cell volumes of SH1000 WT and *pbp3 pbp4* treated with 1x MIC MEM for 1 h as  
829 measured by fluorescence microscopy after NHS-ester Alexa Fluor 555 labelling (Fig. 3a).  
830 Each dot represents a single cell. The median of each distribution is indicated by a black line.

831 The number of cells analysed for each condition was  $n \geq 100$ . *P* value was determined by  
832 Mann–Whitney *U* tests (\*\*\*\*,  $P < 0.0001$ ). From left to right:  $P = 1.276e-042$  and  $1.421e-$   
833  $024$ ;  $n = 102, 100, 101$  and  $102$ .

834 **c**, TEM of SH1000 WT and *pbp3 pbp4* treated with 1x MIC MEM for 1 h. Scale bars 200  
835 nm.


836 **d**, Quantification of phenotypes of SH1000 WT and *pbp3 pbp4* treated with MEM (1x MIC)  
837 for 1 h based on TEM data (Fig. 3c and Fig. 3 – figure supplement 1e, f). Examples of cells  
838 classified as normal (blue) are shown in Fig. 3 – figure supplement 1e, f. Cells with abnormal

839 phenotypes (light blue) are shown in Fig. 3c and Fig. 3 – figure supplement 1e, f. From left to  
840 right  $n= 343, 287, 275$  and 172.

841

842 Data are representative of two (a, b (for WT) independent experiments. Experiments in b (for  
843 *pbp3 pbp4*) and d were performed once.

844



845


846 **Fig. 4 The role of PBP1, PASTA and TP domains in EzrA localisation in *S. aureus*.**

847 **a-c**, Localisation of EzrA-GFP in  $\Delta pbp1$  *ezrA-gfp*,  $pbp1_{\Delta PASTA}$  *ezrA-gfp* and  $pbp1^*$  *ezrA-gfp*  
 848 grown in the presence or absence of IPTG for 2 h and labelled with HADA for 5 min to stain  
 849 PG. Images are average intensity projections of z stacks. Scale bars 5  $\mu$ m.

850 **d**, Quantification of EzrA-GFP localisations in  $\Delta pbp1$  *ezrA-gfp*,  $pbp1_{\Delta PASTA}$  *ezrA-gfp* and  
 851  $pbp1^*$  *ezrA-gfp* grown with or without IPTG. From left to right  $n = 395, 499, 481, 438, 360$   
 852 and 382.

853

854 Data are representative of two independent experiments.



855

856 **Fig. 5 Role of PBP1 PASTA domains in cell wall binding**

857 **a**, Schematic representation of structural domain organization of *S. aureus* PBP1 (top) and  
 858 recombinant proteins (*SaPBP1*, *SaPBP1*<sub>ΔPASTA</sub>, *SaPBP1*\* and *SaPASTA*<sub>PBP1</sub>) used in this  
 859 study. TM, trans-membrane helix (orange); N, N-terminal dimerization domain (red); TP,  
 860 transpeptidase domain (blue); P, PASTA domains (green). The arrowhead indicates the  
 861 inactivation substitution in the TP domain of *SaPBP1*\*. The first and last amino acids of  
 862 constructs are indicated.

863 **b**, Fluorescent cell wall sedimentation assay. A Wilcoxon signed rank test ( $P < 0.05$ ) was  
 864 carried out to assess the significance of difference in +WTA/-WTA PG binding: *SaPBP1*,  
 865  $P = 0.0273$ ; *SaPBP1*\*,  $P = 0.0078$ ; *SaPBP1*<sub>ΔPASTA</sub>,  $P = 0.0195$ ; *SaPASTA*<sub>PBP1</sub>,  $P \geq 0.9999$ ,



866 not significant. Data represent mean  $\pm$  SD. Error bars that are smaller than the symbols are

867 not shown.

868 **c**, Structure of *Sa*PASTA<sub>PBP1</sub>. The crystal structure of *S. aureus* PBP1 lacking the PASTA

869 domains (*Sa*PBP1, PDB 5TRO) and our *Sa*PASTA<sub>PBP1</sub> structure were superimposed on to *S.*

870 *pneumoniae* PBP2<sub>x</sub> (*Sp*PBP2<sub>x</sub>, PDB 5OAU) and displayed as cartoons. Their N-termini are

871 orientated close to the representative cell membrane, as if anchored there by their respective

872 transmembrane helices (dashed red line/orange cylinder). Individual domains are coloured as


873 follows; N-terminal domain (red), transpeptidase domain (blue) and PASTA domain (green).

874 The individual PASTA domains are labelled P1 and P2, respectively. Residues Pro603,

875 Pro661 and Trp666 are displayed as sticks, with nitrogen atoms coloured blue.

876 **Supplementary figures and legends**

877




878

879 **Fig. 1 – figure supplement 1. Essentiality of PBP1, PASTA and TP domains in *S. aureus*.**

880 **a**, Relative levels of PBP1 in  $\Delta bbp1$ ,  $pbp1_{\Delta PASTA}$  and  $pbp1^*$  grown with IPTG and for 0, 1, 2

881 and 3 h after inducer removal. PBP1 levels were normalized to protein levels in SH1000 *lacI*

882 (wt). PBP1 $_{\Delta}$ PASTA levels were normalized to PBP1 $_{\Delta}$ PASTA levels in the presence of inducer.  
883 Quantifications are for the data shown in Fig. 1c. Data represent mean  $\pm$  SD.  
884 **b**, BocillinFL gel-based analysis of penicillin binding proteins in SH1000 *lacI* (wt) and  
885  $\Delta$ *pbp1*, *pbp1* $_{\Delta}$ PASTA and *pbp1*\* grown with IPTG and 0, 1, 2 and 3 h after inducer removal.  
886 **c**, Growth of  $\Delta$ *pbp1*, *pbp1* $_{\Delta}$ PASTA and *pbp1*\* with or without IPTG. Quantifications for the  
887 plate assay are shown in Fig. 1d.  
888 **d**, Growth curves of  $\Delta$ *pbp1*, *pbp1* $_{\Delta}$ PASTA and *pbp1*\* in the presence or absence of IPTG. Data  
889 represent mean  $\pm$  SD. Error bars that are smaller than the data point symbols are not shown.  
890 **e**, Schematic representation of the *pbp1*<sub>STOP</sub> mutant. A SNP (874 G for T) resulted in a  
891 premature stop codon (E292X) and removal of the TP and PASTA domains.  
892 **f**, Schematic representation of domain architecture of PBP1<sub>STOP</sub> encoded by the *pbp1*<sub>STOP</sub>  
893 mutant.  
894 **g**, Immunoblot showing PBP1 levels in SH1000 *lacI* (wt) and *pbp1*<sub>STOP</sub> grown with IPTG and  
895 for 0, 1, 2 and 3 h without inducer analysed using anti-PBP1 antibody. Expected sizes: PBP1  
896 = 83 kDa (black arrowhead) and PBP1<sub>STOP</sub> = 33 kDa (red arrowhead).  
897  
898 Data are representative of two (g), three (a, b, d) and at least four (c) independent  
899 experiments.




900

901 **Fig. 1 – figure supplement 2. Essentiality of PBP1 and its TP activity in Methicillin-**  
 902 **resistant *S. aureus*.**

903 **a**, Schematic representation of evolution of high-level  $\beta$ -lactam resistant  $\Delta pbp1$  and  $pbp1^*$ . A  
 904 single copy *mecA* under its native promoter (*pmecA*) was introduced at the *lysA* locus,  
 905 resulting in low-level oxacillin resistant  $\Delta pbp1 \text{ pmecA}$  and  $pbp1^* \text{ pmecA}$ . Subsequently,  
 906 addition of a point mutation in the *rpoB* gene results in development of high-level resistant  
 907  $\Delta pbp1_{\text{MRSA}}$  and  $pbp1^*$ . Oxacillin MICs shown in brackets were measured using the E-test  
 908 strips.

909 **b**, Plating efficiency of  $\Delta pbp$  (MSSA) and MRSA  $\Delta pbpI_{MRSA}$  cells upon the inducer removal  
910 compared to the control groups grown in the presence of inducer. Data represent mean  $\pm$  SD.  
911  $P$  value was determined by Mann–Whitney  $U$  tests.  $P = 0.5429$  (NS, not significant).  
912 **c**, Growth curves of  $\Delta pbpI_{MRSA}$  and  $pbpI^*_{MRSA}$  in the presence or absence of IPTG. Data  
913 represent mean  $\pm$  SD. Error bars that are smaller than the data point symbols are not shown.  
914 **d**, Growth of  $\Delta pbpI_{MRSA}$  and  $pbpI^*_{MRSA}$  with or without IPTG. Quantifications for  
915  $\Delta pbpI_{MRSA}$  are shown in Fig. 1 – figure supplement 2c and for  $pbpI^*_{MRSA}$  are shown in Fig.  
916 1b.  
917  
918 Data are representative of at least three independent experiments.



919

920 **Fig. 2 – figure supplement 1. Loss of PBP1, PASTAs or TP activity of PBP1 does not**  
 921 **prevent PG synthesis.**


922 **a-c**, PG incorporation in *pbp4* mutants depleted of PBP1.  $\Delta pbp1 pbp4$ ,  $pbp1_{\Delta PASTA} pbp4$  and  
 923  $pbp1^* pbp4$  grown with or without IPTG for 2 h and incubated with HADA for 5 min to  
 924 show nascent PG incorporation.

925 **d-f**,  $\Delta pbp1$ ,  $pbp1_{\Delta PASTA}$  and  $pbp1^*$  grown with or without IPTG for 2 h, incubated with  
 926 dipeptide (ADA-DA) for 5 min and clicked to Alexa Fluor 488 to show nascent PG  
 927 incorporation.

928 Fluorescence images are average intensity projections of  $z$  stacks. Scale bars 2  $\mu\text{m}$ .

929

930 Images are representatives of two independent experiments.



931

932 **Fig. 2 – figure supplement 2. Role of PBP1 in *S. aureus***



933 **a**, Fluorescence images of SH1000 WT labelled with HADA for 5 min (nascent PG) and  
934 counter labelled with NHS-ester Alexa Fluor 555 (cell wall). Images are average intensity  
935 projections of *z* stacks. Scale bars 2  $\mu$ m.


936 **b**, TEM of  $\Delta$ *pbp1*, *pbp1* <sub>$\Delta$ PASTA</sub> and *pbp1*\* grown in the presence of IPTG categorised as  
937 normal phenotype (blue). Scale bars 500 nm.

938 **c**, TEM of  $\Delta$ *pbp1*, *pbp1* <sub>$\Delta$ PASTA</sub> and *pbp1*\* grown in the absence of IPTG for 2 h categorised  
939 as abnormal phenotype (1, PG blebs; 2, thickened cell wall; 3, thickened complete septum; 4,  
940 multiple septa; 5, misshapen incomplete septum; 6, thick incomplete septum with rounded  
941 leading edge; 7, curved septum; 8, separation defect. Scale bars 500 nm.

942 **d**, Fluorescence images of *pbp1*\* *pbp3* *pbp4* grown with or without IPTG for 2 h, labelled  
943 with HADA for 5 min (nascent PG) and counter stained with NHS-ester Alexa Fluor 555  
944 (cell wall). Images are average intensity projections of *z* stacks. Scale bars 2  $\mu$ m.

945

946 Data are representative of two independent experiments.



947

948 **Fig. 2 – figure supplement 3. Gallery of AFM images of *S. aureus*  $\Delta pbp1$ ,  $pbp1_{\Delta PASTA}$  and**  
949  **$pbp1^*$**

950 **a**, AFM topographic images of unfinished (i) and closed (ii) septa in *S. aureus* SH1000.

951 Sacculi (images to the left, scale bars 500 nm, data scales (z): 200 (top) and 250 nm (bottom))

952 and higher magnification scans (images to the right, scale bars 50 nm, data scales (z): 80 (top)

953 and 40 nm (bottom)) on the boxed areas from the images to the left.

954 **b**, AFM topographic images of unfinished septa in  $\Delta pbp1$  (from left to right: scale bars 500,

955 50 and 50 nm; data scales (z) 500, 120 and 150 nm),  $pbp1_{\Delta PASTA}$  (from left to right: scale bars


956 500, 50 and 50 nm; data scales (z) 693, 80 and 100 nm) and  $pbp1^*$  (from left to right: scale

957 bars 500, 50 and 50 nm; data scales ( $z$ ) 500, 80 and 25 nm) grown in the absence of inducer  
958 for 2 h. Images to the left are sacculi, while images in the centre (1) and to the right (2) are  
959 higher magnification scans on the boxed areas of the images on the left.

960 **c**, AFM topographic images of external nascent ring architecture in SH1000 WT (*wt*; scale  
961 bars: from left to right: scale bars 500 and 50 nm; data scales ( $z$ ) 100 and 20 nm) and mutants  
962  $\Delta pbp1$  (scale bars: from left to right: scale bars 500 and 50 nm; data scales ( $z$ ) 400 and 60  
963 nm) and  $pbp1_{\Delta PASTA}$  (scale bars: from left to right: scale bars 500 and 50 nm; data scales ( $z$ )  
964 350 and 100 nm) grown in the absence of inducer for 2 h. Images to the left are sacculi, while  
965 images to the right are higher magnification scans on the boxed areas of the images on the  
966 left. The arrowheads indicate abnormal features, holes.

967

968 Data are representative of two independent experiments.



969

970 **Fig. 3 – figure supplement 1. Effect of meropenem (MEM) on *S. aureus*.**

971 **a-b**, Bactericidal effect of addition of 0.5x, 1x, 5x and 10x MIC MEM on (a) SH1000 WT  
 972 and (b) *pbp3 pbp4* (b). MEM MIC is 0.4  $\mu\text{g/ml}$  and 0.2  $\mu\text{g/ml}$  for SH1000 WT and *pbp3*  
 973 *pbp4*, respectively Data represent mean  $\pm$  SD. Error bars that are symbols than the dots are  
 974 not shown. The dotted line is the detection limit.


975 **c**, Quantification of cellular phenotypes of SH1000 WT treated with 1x MIC MEM for 1 h  
976 based on HADA incorporation (Fig 3a). Same phenotype classification was used as shown in  
977 Fig. 2c. From left to right  $n = 309$  and  $355$ .

978 **d**, Fluorescence images of *pbp3 pbp4* treated with 1x MIC MEM for 1 h, labelled with  
979 HADA for 5 min to show nascent PG and counter labelled with NHS-ester Alexa Fluor 555  
980 (cell wall). Images are average intensity projections of  $z$  stacks. Scale bars  $2 \mu\text{m}$ . Phenotype  
981 classification of MEM treated *pbp3 pbp4* was not possible due to low HADA fluorescence  
982 signal.

983 **e-f**, TEM of SH1000 WT (**e**) and *pbp3 pbp4* (**f**) grown with or without 1x MIC MEM for 1 h.  
984 Scale bars 200 nm. Examples of cells categorised as normal phenotype are in blue, cells with  
985 abnormal phenotype are in light blue (1, asymmetric septum ingrowth; 2, off-septal PG  
986 thickening; 3, septum with rounded leading edge; 4, curved septum).

987

988 Data are representative of three (a and b) and two (c) independent experiments. Experiments  
989 in d, e and f were performed once.



990

991 **Fig. 4 – figure supplement 1. Functional association between PBP1 and WTA**

992 **a**, Fluorescence images of the *tarO* mutant labelled with HADA for 5 min (nascent PG) and

993 counter stained with NHS-ester Alexa Fluor 555 (cell wall). Images are average intensity

994 projections of z stacks. Scale bars 5  $\mu\text{m}$ .


995 **b-d**, *Δpbp1 tarO*, *pbp1<sub>ΔPASTA</sub> tarO* and *pbp1\* tarO* grown with or without IPTG for 2 h,

996 incubated with HADA for 5 min to show nascent PG and counter labelled with NHS-ester

997 Alexa Fluor 555 (cell wall). Images are average intensity projections of  $z$  stacks. Scale bars 5  
998  $\mu\text{m}$ .

999 **e**, Cell volumes of *tarO* and  $\Delta\text{pbp1 } tarO$ , *pbp1* $_{\Delta\text{PASTA}}$  *tarO* and *pbp1*\* *tarO* grown with or  
1000 without IPTG as measured by fluorescence microscopy after NHS-ester Alexa Fluor 555  
1001 labelling. Each dot represents a single cell. The median of each distribution is indicated by a  
1002 black line. The number of cells analysed for each mutant and condition was  $n \geq 100$ .  $P$  value  
1003 was determined by Mann–Whitney  $U$  tests (\*\*\*,  $P < 0.0001$ ). From left to right:  $P = 2.243\text{e-}$   
1004  $022$ ,  $1.460\text{e-}037$  and  $8.074\text{e-}029$ ;  $n = 100, 102, 101, 100, 100, 100$  and  $100$ .

1005 **f**, Quantification of cellular phenotypes for *tarO* and  $\Delta\text{pbp1 } tarO$ , *pbp1* $_{\Delta\text{PASTA}}$  *tarO* and  
1006 *pbp1*\* *tarO* based on HADA incorporation (Fig. 4 – figure supplement 1a-d) after incubation  
1007 with or without IPTG. From left to right  $n = 306, 253, 271, 358, 266, 313$  and  $336$ .  
1008  
1009 Data are representative of two independent experiments.



1010

1011 **Fig. 5 – figure supplement 1. The role of PBP1 PASTA domains in interactions with cell**  
 1012 **division components and PG.**

1013 **a**, Bacterial two-hybrid analysis of the effect of PASTA domains truncation on PBP1

1014 interaction with its known interaction partners; empty, T18 with no insert; zip, T18 with a

1015 leucine zipper fragment; *ve+*, positive control (T18-*zip*/T25-*zip*); *ve-*, negative control

1016 (T18/T25).

1017 **b**, Quantitative bacterial two-hybrid analysis of the effect of the PASTA domains truncation

1018 on PBP1 interaction with cell division components determined by analysis of the  $\beta$ -

1019 galactosidase activities of *E. coli* BTH101 cells harbouring the corresponding plasmids.

1020 Dotted line, the positive interaction cut off value (4-fold greater than the pair of T18/T25).

1021 Data represent mean  $\pm$  SD. *P* value was determined by Mann–Whitney *U* tests (\*, *P* < 0.05).

1022 DivIB (PBP1 vs PBP1<sub>ΔPASTA</sub>) *P* = 0.0424, FtsW (PBP1 vs PBP1<sub>ΔPASTA</sub>) *P* = 0.0163.

1023 **c**, Coomassie-stained SDS-PAGE gel (left) and BocillinFL gel-based analysis (right) of

1024 purified recombinant *SaPBP1*, *SaPBP1\**, *SaPBP1<sub>ΔPASTA</sub>* and *SaPASTA<sub>PBP1</sub>*. Bands


1025 corresponding to *SaPBP1* and *SaPBP1<sub>ΔPASTA</sub>* were fluorescent, indicating their covalent

1026 binding to BocillinFL. Bands corresponding to *SaPBP1\** and *SaPASTA<sub>PBP1</sub>* were not

1027 fluorescent, and were therefore unable to bind BocillinFL. *SaPBP1* incubated with ampicillin



- 1028 prior to BocillinFL incubation failed to fluoresce, consistent with specific binding of
- 1029 BocillinFL to the TP domain. Expected sizes: *SaPBP1* and *SaPBP1\**, 80.5kDa;
- 1030 *SaPBP1*<sub>ΔPASTA</sub>, 64.5 kDa; *SaPASTA*<sub>PBP1</sub>, 18.2 kDa.
- 1031
- 1032 Data are representative of two (c) and three (a-b) independent experiments.



1033

1034 **Fig. 5 – figure supplement 2. Conceptual model of septum formation in *S. aureus*.**

1035 (a, b) The growing *S. aureus* cell increases in volume (Zhou et al., 2015). (c) Septal synthesis  
 1036 starts by formation of the piecrust (red) (Turner et al., 2010). (d, e) ‘V’ shaped septum (Lund  
 1037 et al., 2018) progresses inwards by insertion of ring like structured PG synthesised by PBP1-  
 1038 FtsW at the septum core and mesh structured PG produced by PBP2. (f) The annulus closes  
 1039 resulting in a bowed septum. (g) Septum is filled out by peptidoglycan insertion executed by  
 1040 PBP2 and this continues until the cross wall is of uniform thickness (Lund et al., 2018). (h)  
 1041 Cell wall is hydrolysed at the plane of septation. (i) Daughter cells separate. The cell wall of  
 1042 the daughter cell (coloured insets) is a chimera of the old cell wall with both internally and  
 1043 externally mesh structured PG and a nascent cell wall with the external ring structured PG  
 1044 and the mesh-like cytoplasmic facing PG (Pasquina-Lemonche et al., 2020).

## 1045 **References**

- 1046 Arnaud, M., Chastanet, A., & Débarbouillé, M. (2004). New vector for efficient allelic  
1047 replacement in naturally nontransformable, low-GC-content, gram-positive bacteria.  
1048 *Applied and Environmental Microbiology*, *70*(11), 6887–6891.  
1049 <https://doi.org/10.1128/AEM.70.11.6887-6891.2004>
- 1050 Atilano, M. L., Pereira, P. M., Yates, J., Reed, P., Veiga, H., Pinho, M. G., & Filipe, S. R.  
1051 (2010). Teichoic acids are temporal and spatial regulators of peptidoglycan cross-  
1052 linking in *Staphylococcus aureus*. *Proceedings of the National Academy of Sciences*  
1053 *of the United States of America*, *107*(44), 18991–18996.  
1054 <https://doi.org/10.1073/pnas.1004304107>
- 1055 Barthe, P., Mukamolova, G. V., Roumestand, C., & Cohen-Gonsaud, M. (2010). The  
1056 Structure of PknB Extracellular PASTA Domain from *Mycobacterium tuberculosis*  
1057 Suggests a Ligand-Dependent Kinase Activation. *Structure*, *18*(5), 606–615.  
1058 <https://doi.org/10.1016/j.str.2010.02.013>
- 1059 Bernardo-García, N., Mahasenan, K. V., Batuecas, M. T., Lee, M., Heseck, D., Petráčková, D.,  
1060 Doubravová, L., Branny, P., Mobashery, S., & Hermoso, J. A. (2018). Allostery,  
1061 Recognition of Nascent Peptidoglycan, and Cross-linking of the Cell Wall by the  
1062 Essential Penicillin-Binding Protein 2x of *Streptococcus pneumoniae*. *ACS Chemical*  
1063 *Biology*, *13*(3), 694–702. <https://doi.org/10.1021/acscchembio.7b00817>
- 1064 Berrow, N. S., Alderton, D., & Owens, R. J. (2009). The precise engineering of expression  
1065 vectors using high-throughput In-Fusion PCR cloning. *Methods in Molecular Biology*  
1066 *(Clifton, N.J.)*, *498*, 75–90. [https://doi.org/10.1007/978-1-59745-196-3\\_5](https://doi.org/10.1007/978-1-59745-196-3_5)
- 1067 Berti, A. D., Sakoulas, G., Nizet, V., Tewhey, R., & Rose, W. E. (2013).  $\beta$ -Lactam  
1068 Antibiotics Targeting PBP1 Selectively Enhance Daptomycin Activity against

- 1069 Methicillin-Resistant *Staphylococcus aureus*. *Antimicrobial Agents and*  
1070 *Chemotherapy*, 57(10), 5005–5012. <https://doi.org/10.1128/AAC.00594-13>
- 1071 Bertsche, U., Kast, T., Wolf, B., Fraipont, C., Aarsman, M. E. G., Kannenberg, K., von  
1072 Rechenberg, M., Nguyen-Distèche, M., den Blaauwen, T., Höltje, J.-V., & Vollmer,  
1073 W. (2006). Interaction between two murein (peptidoglycan) synthases, PBP3 and  
1074 PBP1B, in *Escherichia coli*. *Molecular Microbiology*, 61(3), 675–690.  
1075 <https://doi.org/10.1111/j.1365-2958.2006.05280.x>
- 1076 Bottomley, A. L., Kabli, A. F., Hurd, A. F., Turner, R. D., Garcia-Lara, J., & Foster, S. J.  
1077 (2014). *Staphylococcus aureus* DivIB is a peptidoglycan-binding protein that is  
1078 required for a morphological checkpoint in cell division. *Molecular Microbiology*.  
1079 <https://doi.org/10.1111/mmi.12813>
- 1080 Bunkóczi, G., & Read, R. J. (2011). Improvement of molecular-replacement models with  
1081 Sculptor. *Acta Crystallographica. Section D, Biological Crystallography*, 67(Pt 4),  
1082 303–312. <https://doi.org/10.1107/S0907444910051218>
- 1083 Calvanese, L., Falcigno, L., Squeglia, F., D’Auria, G., & Berisio, R. (2017). Structural and  
1084 dynamic features of PASTA domains with different functional roles. *Journal of*  
1085 *Biomolecular Structure and Dynamics*, 35(10), 2293–2300.  
1086 <https://doi.org/10.1080/07391102.2016.1217274>
- 1087 Campbell, J., Singh, A. K., Santa Maria, J. P., Kim, Y., Brown, S., Swoboda, J. G.,  
1088 Mylonakis, E., Wilkinson, B. J., & Walker, S. (2011). Synthetic lethal compound  
1089 combinations reveal a fundamental connection between wall teichoic acid and  
1090 peptidoglycan biosyntheses in *Staphylococcus aureus*. *ACS Chemical Biology*, 6(1),  
1091 106–116. <https://doi.org/10.1021/cb100269f>
- 1092 Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J.,  
1093 Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010). MolProbity: All-atom

- 1094 structure validation for macromolecular crystallography. *Acta Crystallographica*.
- 1095 *Section D, Biological Crystallography*, 66(Pt 1), 12–21.
- 1096 <https://doi.org/10.1107/S0907444909042073>
- 1097 Cho, H., Wivagg, C. N., Kapoor, M., Barry, Z., Rohs, P. D. A., Suh, H., Marto, J. A., Garner,
- 1098 E. C., & Bernhardt, T. G. (2016). Bacterial cell wall biogenesis is mediated by SEDS
- 1099 and PBP polymerase families functioning semi-autonomously. *Nature Microbiology*,
- 1100 1(10), 1–8. <https://doi.org/10.1038/nmicrobiol.2016.172>
- 1101 Cooper, E. L., García-Lara, J., & Foster, S. J. (2009). YsxC, an essential protein in
- 1102 *Staphylococcus aureus* crucial for ribosome assembly/stability. *BMC Microbiology*, 9,
- 1103 266. <https://doi.org/10.1186/1471-2180-9-266>
- 1104 Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010). Features and development of
- 1105 Coot. *Acta Crystallographica. Section D, Biological Crystallography*, 66(Pt 4), 486–
- 1106 501. <https://doi.org/10.1107/S0907444910007493>
- 1107 Erster, O., & Liscovitch, M. (2010). A modified inverse PCR procedure for insertion,
- 1108 deletion, or replacement of a DNA fragment in a target sequence and its application in
- 1109 the ligand interaction scan method for generation of ligand-regulated proteins.
- 1110 *Methods in Molecular Biology (Clifton, N.J.)*, 634, 157–174.
- 1111 [https://doi.org/10.1007/978-1-60761-652-8\\_12](https://doi.org/10.1007/978-1-60761-652-8_12)
- 1112 Evans, P. R., & Murshudov, G. N. (2013). How good are my data and what is the resolution?
- 1113 *Acta Crystallographica. Section D, Biological Crystallography*, 69(Pt 7), 1204–1214.
- 1114 <https://doi.org/10.1107/S0907444913000061>
- 1115 Farha, M. A., Leung, A., Sewell, E. W., D’Elia, M. A., Allison, S. E., Ejim, L., Pereira, P.
- 1116 M., Pinho, M. G., Wright, G. D., & Brown, E. D. (2013). Inhibition of WTA synthesis
- 1117 blocks the cooperative action of PBPs and sensitizes MRSA to  $\beta$ -lactams. *ACS*
- 1118 *Chemical Biology*, 8(1), 226–233. <https://doi.org/10.1021/cb300413m>

- 1119 Fey, P. D., Endres, J. L., Yajjala, V. K., Widhelm, T. J., Boissy, R. J., Bose, J. L., & Bayles,  
1120 K. W. (2013). A genetic resource for rapid and comprehensive phenotype screening  
1121 of nonessential *Staphylococcus aureus* genes. *MBio*, *4*(1), e00537-00512.  
1122 <https://doi.org/10.1128/mBio.00537-12>
- 1123 García-Lara, J., Weihs, F., Ma, X., Walker, L., Chaudhuri, R. R., Kasturiarachchi, J.,  
1124 Crossley, H., Golestanian, R., & Foster, S. J. (2015). Supramolecular structure in the  
1125 membrane of *Staphylococcus aureus*. *Proceedings of the National Academy of*  
1126 *Sciences*, *112*(51), 15725–15730. <https://doi.org/10.1073/pnas.1509557112>
- 1127 Gibson, D. G., Young, L., Chuang, R.-Y., Venter, J. C., Hutchison, C. A., & Smith, H. O.  
1128 (2009). Enzymatic assembly of DNA molecules up to several hundred kilobases.  
1129 *Nature Methods*, *6*(5), 343–345. <https://doi.org/10.1038/nmeth.1318>
- 1130 Holm, L. (2020). DALI and the persistence of protein shape. *Protein Science: A Publication*  
1131 *of the Protein Society*, *29*(1), 128–140. <https://doi.org/10.1002/pro.3749>
- 1132 Horsburgh, M. J., Aish, J. L., White, I. J., Shaw, L., Lithgow, J. K., & Foster, S. J. (2002).  $\sigma$ B  
1133 Modulates Virulence Determinant Expression and Stress Resistance: Characterization  
1134 of a Functional *rsbU* Strain Derived from *Staphylococcus aureus* 8325-4. *Journal of*  
1135 *Bacteriology*, *184*(19), 5457–5467. [https://doi.org/10.1128/JB.184.19.5457-](https://doi.org/10.1128/JB.184.19.5457-5467.2002)  
1136 [5467.2002](https://doi.org/10.1128/JB.184.19.5457-5467.2002)
- 1137 Hudson, K. L., Bartlett, G. J., Diehl, R. C., Agirre, J., Gallagher, T., Kiessling, L. L., &  
1138 Woolfson, D. N. (2015). Carbohydrate-Aromatic Interactions in Proteins. *Journal of*  
1139 *the American Chemical Society*, *137*(48), 15152–15160.  
1140 <https://doi.org/10.1021/jacs.5b08424>
- 1141 Hutter, J. L., & Bechhoefer, J. (1993). Calibration of atomic-force microscope tips. *Review of*  
1142 *Scientific Instruments*, *64*(7), 1868–1873. <https://doi.org/10.1063/1.1143970>

- 1143 Kabsch, W. (2010). XDS. *Acta Crystallographica. Section D, Biological Crystallography*,  
1144 66(Pt 2), 125–132. <https://doi.org/10.1107/S0907444909047337>
- 1145 Karimova, G., Ullmann, A., & Ladant, D. (2001). Protein-protein interaction between  
1146 *Bacillus stearothermophilus* tyrosyl-tRNA synthetase subdomains revealed by a  
1147 bacterial two-hybrid system. *Journal of Molecular Microbiology and Biotechnology*,  
1148 3(1), 73–82.
- 1149 Kreiswirth, B. N., Löfdahl, S., Betley, M. J., O'Reilly, M., Schlievert, P. M., Bergdoll, M. S.,  
1150 & Novick, R. P. (1983). The toxic shock syndrome exotoxin structural gene is not  
1151 detectably transmitted by a prophage. *Nature*, 305(5936), 709–712.  
1152 <https://doi.org/10.1038/305709a0>
- 1153 Krissinel, E., & Henrick, K. (2007). Inference of macromolecular assemblies from crystalline  
1154 state. *Journal of Molecular Biology*, 372(3), 774–797.  
1155 <https://doi.org/10.1016/j.jmb.2007.05.022>
- 1156 Kuru, E., Radkov, A., Meng, X., Egan, A., Alvarez, L., Dowson, A., Booher, G., Breukink,  
1157 E., Roper, D. I., Cava, F., Vollmer, W., Brun, Y., & VanNieuwenhze, M. S. (2019).  
1158 Mechanisms of Incorporation for D-Amino Acid Probes That Target Peptidoglycan  
1159 Biosynthesis. *ACS Chemical Biology*, 14(12), 2745–2756.  
1160 <https://doi.org/10.1021/acscchembio.9b00664>
- 1161 Lee, C. Y., Buranen, S. L., & Ye, Z. H. (1991). Construction of single-copy integration  
1162 vectors for *Staphylococcus aureus*. *Gene*, 103(1), 101–105.  
1163 [https://doi.org/10.1016/0378-1119\(91\)90399-v](https://doi.org/10.1016/0378-1119(91)90399-v)
- 1164 Liebschner, D., Afonine, P. V., Baker, M. L., Bunkóczi, G., Chen, V. B., Croll, T. I., Hintze,  
1165 B., Hung, L. W., Jain, S., McCoy, A. J., Moriarty, N. W., Oeffner, R. D., Poon, B. K.,  
1166 Prisant, M. G., Read, R. J., Richardson, J. S., Richardson, D. C., Sammito, M. D.,  
1167 Sobolev, O. V., ... Adams, P. D. (2019). Macromolecular structure determination

- 1168 using X-rays, neutrons and electrons: Recent developments in Phenix. *Acta*  
1169 *Crystallographica. Section D, Structural Biology*, 75(Pt 10), 861–877.  
1170 <https://doi.org/10.1107/S2059798319011471>
- 1171 Loskill, P., Pereira, P. M., Jung, P., Bischoff, M., Herrmann, M., Pinho, M. G., & Jacobs, K.  
1172 (2014). Reduction of the peptidoglycan crosslinking causes a decrease in stiffness of  
1173 the *Staphylococcus aureus* cell envelope. *Biophysical Journal*, 107(5), 1082–1089.  
1174 <https://doi.org/10.1016/j.bpj.2014.07.029>
- 1175 Lund, V. A., Wacnik, K., Turner, R. D., Cotterell, B. E., Walther, C. G., Fenn, S. J., Grein,  
1176 F., Wollman, A. J., Leake, M. C., Olivier, N., Cadby, A., Mesnage, S., Jones, S., &  
1177 Foster, S. J. (2018). Molecular coordination of *Staphylococcus aureus* cell division.  
1178 *ELife*, 7, e32057. <https://doi.org/10.7554/eLife.32057>
- 1179 Maurer, P., Todorova, K., Sauerbier, J., & Hakenbeck, R. (2012). Mutations in *Streptococcus*  
1180 *pneumoniae* penicillin-binding protein 2x: Importance of the C-terminal penicillin-  
1181 binding protein and serine/threonine kinase-associated domains for beta-lactam  
1182 binding. *Microbial Drug Resistance (Larchmont, N.Y.)*, 18(3), 314–321.  
1183 <https://doi.org/10.1089/mdr.2012.0022>
- 1184 McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read,  
1185 R. J. (2007). Phaser crystallographic software. *Journal of Applied Crystallography*,  
1186 40(Pt 4), 658–674. <https://doi.org/10.1107/S0021889807021206>
- 1187 Meeske, A. J., Riley, E. P., Robins, W. P., Uehara, T., Mekalanos, J. J., Kahne, D., Walker,  
1188 S., Kruse, A. C., Bernhardt, T. G., & Rudner, D. Z. (2016). SEDS proteins are a  
1189 widespread family of bacterial cell wall polymerases. *Nature*, 537(7622), 634–638.  
1190 <https://doi.org/10.1038/nature19331>
- 1191 Mir, M., Asong, J., Li, X., Cardot, J., Boons, G.-J., & Husson, R. N. (2011). The  
1192 Extracytoplasmic Domain of the *Mycobacterium tuberculosis* Ser/Thr Kinase PknB



- 1193 Binds Specific Muropeptides and Is Required for PknB Localization. *PLOS*  
1194 *Pathogens*, 7(7), e1002182. <https://doi.org/10.1371/journal.ppat.1002182>
- 1195 Morales Angeles, D., Macia-Valero, A., Bohorquez, L. C., & Scheffers, D.-J. (2020). The  
1196 PASTA domains of *Bacillus subtilis* PBP2B strengthen the interaction of PBP2B with  
1197 DivIB. *Microbiology (Reading, England)*, 166(9), 826–836.  
1198 <https://doi.org/10.1099/mic.0.000957>
- 1199 Neuhaus, F. C., & Baddiley, J. (2003). A continuum of anionic charge: Structures and  
1200 functions of D-alanyl-teichoic acids in gram-positive bacteria. *Microbiology and*  
1201 *Molecular Biology Reviews: MMBR*, 67(4), 686–723.  
1202 <https://doi.org/10.1128/membr.67.4.686-723.2003>
- 1203 Novick, R. P., & Morse, S. I. (1967). In vivo transmission of drug resistance factors between  
1204 strains of *Staphylococcus aureus*. *The Journal of Experimental Medicine*, 125(1), 45–  
1205 59. <https://doi.org/10.1084/jem.125.1.45>
- 1206 Panchal, V. V., Griffiths, C., Mosaei, H., Bilyk, B., Sutton, J. A. F., Carnell, O. T., Hornby,  
1207 D. P., Green, J., Hobbs, J. K., Kelley, W. L., Zenkin, N., & Foster, S. J. (2020).  
1208 Evolving MRSA: High-level  $\beta$ -lactam resistance in *Staphylococcus aureus* is  
1209 associated with RNA Polymerase alterations and fine tuning of gene expression. *PLoS*  
1210 *Pathogens*, 16(7), e1008672. <https://doi.org/10.1371/journal.ppat.1008672>
- 1211 Pasquina-Lemonche, L., Burns, J., Turner, R. D., Kumar, S., Tank, R., Mullin, N., Wilson, J.  
1212 S., Chakrabarti, B., Bullough, P. A., Foster, S. J., & Hobbs, J. K. (2020). The  
1213 architecture of the Gram-positive bacterial cell wall. *Nature*, 582(7811), 294–297.  
1214 <https://doi.org/10.1038/s41586-020-2236-6>
- 1215 Pereira, S. F. F., Henriques, A. O., Pinho, M. G., de Lencastre, H., & Tomasz, A. (2007).  
1216 Role of PBP1 in cell division of *Staphylococcus aureus*. *Journal of Bacteriology*,  
1217 189(9), 3525–3531. <https://doi.org/10.1128/JB.00044-07>

- 1218 Pereira, S. F. F., Henriques, A. O., Pinho, M. G., de Lencastre, H., & Tomasz, A. (2009).  
1219 Evidence for a dual role of PBP1 in the cell division and cell separation of  
1220 *Staphylococcus aureus*. *Molecular Microbiology*, 72(4), 895–904.  
1221 <https://doi.org/10.1111/j.1365-2958.2009.06687.x>
- 1222 Pinho, M. G., de Lencastre, H., & Tomasz, A. (2001). An acquired and a native penicillin-  
1223 binding protein cooperate in building the cell wall of drug-resistant staphylococci.  
1224 *Proceedings of the National Academy of Sciences of the United States of America*,  
1225 98(19), 10886–10891. <https://doi.org/10.1073/pnas.191260798>
- 1226 Pinho, M. G., & Errington, J. (2005). Recruitment of penicillin-binding protein PBP2 to the  
1227 division site of *Staphylococcus aureus* is dependent on its transpeptidation substrates.  
1228 *Molecular Microbiology*, 55(3), 799–807. <https://doi.org/10.1111/j.1365->  
1229 [2958.2004.04420.x](https://doi.org/10.1111/j.1365-2958.2004.04420.x)
- 1230 Pinho, M. G., Filipe, S. R., de Lencastre, H., & Tomasz, A. (2001). Complementation of the  
1231 essential peptidoglycan transpeptidase function of penicillin-binding protein 2 (PBP2)  
1232 by the drug resistance protein PBP2A in *Staphylococcus aureus*. *Journal of*  
1233 *Bacteriology*, 183(22), 6525–6531. <https://doi.org/10.1128/JB.183.22.6525->  
1234 [6531.2001](https://doi.org/10.1128/JB.183.22.6525-6531.2001)
- 1235 Pinho, M. G., Kjos, M., & Veening, J.-W. (2013). How to get (a)round: Mechanisms  
1236 controlling growth and division of coccoid bacteria. *Nature Reviews. Microbiology*,  
1237 11(9), 601–614. <https://doi.org/10.1038/nrmicro3088>
- 1238 Reed, P., Atilano, M. L., Alves, R., Hoiczky, E., Sher, X., Reichmann, N. T., Pereira, P. M.,  
1239 Roemer, T., Filipe, S. R., Pereira-Leal, J. B., Ligoxygakis, P., & Pinho, M. G. (2015).  
1240 *Staphylococcus aureus* Survives with a Minimal Peptidoglycan Synthesis Machine  
1241 but Sacrifices Virulence and Antibiotic Resistance. *PLoS Pathogens*, 11(5),  
1242 e1004891. <https://doi.org/10.1371/journal.ppat.1004891>

- 1243 Reichmann, N. T., Tavares, A. C., Saraiva, B. M., Jousselin, A., Reed, P., Pereira, A. R.,  
1244 Monteiro, J. M., Sobral, R. G., VanNieuwenhze, M. S., Fernandes, F., & Pinho, M. G.  
1245 (2019). SEDS-bPBP pairs direct lateral and septal peptidoglycan synthesis in  
1246 *Staphylococcus aureus*. *Nature Microbiology*, *4*(8), 1368–1377.  
1247 <https://doi.org/10.1038/s41564-019-0437-2>
- 1248 Ruggiero, A., Squeglia, F., Marasco, D., Marchetti, R., Molinaro, A., & Berisio, R. (2011).  
1249 X-ray structural studies of the entire extracellular region of the serine/threonine kinase  
1250 PrkC from *Staphylococcus aureus*. *The Biochemical Journal*, *435*(1), 33–41.  
1251 <https://doi.org/10.1042/BJ20101643>
- 1252 Sader, J. E., Borgani, R., Gibson, C. T., Haviland, D. B., Higgins, M. J., Kilpatrick, J. I., Lu,  
1253 J., Mulvaney, P., Shearer, C. J., Slattery, A. D., Thorén, P.-A., Tran, J., Zhang, H.,  
1254 Zhang, H., & Zheng, T. (2016). A virtual instrument to standardise the calibration of  
1255 atomic force microscope cantilevers. *Review of Scientific Instruments*, *87*(9), 093711.  
1256 <https://doi.org/10.1063/1.4962866>
- 1257 Sambrook, J., Fritsch, E. F., & Maniatis, T. (1989). *Molecular cloning: A laboratory manual*.  
1258 *Molecular Cloning: A Laboratory Manual*, Ed. 2.  
1259 <https://www.cabdirect.org/cabdirect/abstract/19901616061>
- 1260 Saraiva, B. M., Sorg, M., Pereira, A. R., Ferreira, M. J., Caulat, L. C., Reichmann, N. T., &  
1261 Pinho, M. G. (2020). Reassessment of the distinctive geometry of *Staphylococcus*  
1262 *aureus* cell division. *Nature Communications*, *11*(1), 4097.  
1263 <https://doi.org/10.1038/s41467-020-17940-9>
- 1264 Schenk, S., & Laddaga, R. A. (1992). Improved method for electroporation of  
1265 *Staphylococcus aureus*. *FEMS Microbiology Letters*, *73*(1–2), 133–138.  
1266 [https://doi.org/10.1016/0378-1097\(92\)90596-g](https://doi.org/10.1016/0378-1097(92)90596-g)

- 1267 Schneider, T., & Sahl, H.-G. (2010). An oldie but a goodie—Cell wall biosynthesis as  
1268 antibiotic target pathway. *International Journal of Medical Microbiology: IJMM*,  
1269 *300*(2–3), 161–169. <https://doi.org/10.1016/j.ijmm.2009.10.005>
- 1270 Shah, I. M., Laaberki, M.-H., Popham, D. L., & Dworkin, J. (2008). A Eukaryotic-like  
1271 Ser/Thr Kinase Signals Bacteria to Exit Dormancy in Response to Peptidoglycan  
1272 Fragments. *Cell*, *135*(3), 486–496. <https://doi.org/10.1016/j.cell.2008.08.039>
- 1273 Silhavy, T. J., Kahne, D., & Walker, S. (2010). The bacterial cell envelope. *Cold Spring*  
1274 *Harbor Perspectives in Biology*, *2*(5), a000414.  
1275 <https://doi.org/10.1101/cshperspect.a000414>
- 1276 Squeglia, F., Marchetti, R., Ruggiero, A., Lanzetta, R., Marasco, D., Dworkin, J., Petoukhov,  
1277 M., Molinaro, A., Berisio, R., & Silipo, A. (2011). Chemical Basis of Peptidoglycan  
1278 Discrimination by PrkC, a Key Kinase Involved in Bacterial Resuscitation from  
1279 Dormancy. *Journal of the American Chemical Society*, *133*(51), 20676–20679.  
1280 <https://doi.org/10.1021/ja208080r>
- 1281 Srisuknimit, V., Qiao, Y., Schaefer, K., Kahne, D., & Walker, S. (2017). Peptidoglycan  
1282 Cross-Linking Preferences of *Staphylococcus aureus* Penicillin-Binding Proteins  
1283 Have Implications for Treating MRSA Infections. *Journal of the American Chemical*  
1284 *Society*, *139*(29), 9791–9794. <https://doi.org/10.1021/jacs.7b04881>
- 1285 Steele, V. R., Bottomley, A. L., Garcia-Lara, J., Kasturiarachchi, J., & Foster, S. J. (2011).  
1286 Multiple essential roles for EzrA in cell division of *Staphylococcus aureus*. *Molecular*  
1287 *Microbiology*, *80*(2), 542–555. <https://doi.org/10.1111/j.1365-2958.2011.07591.x>
- 1288 Straume, D., Piechowiak, K. W., Olsen, S., Stamsås, G. A., Berg, K. H., Kjos, M.,  
1289 Heggenhougen, M. V., Alcorlo, M., Hermoso, J. A., & Håvarstein, L. S. (2020). Class  
1290 A PBPs have a distinct and unique role in the construction of the pneumococcal cell

- 1291 wall. *Proceedings of the National Academy of Sciences of the United States of*  
1292 *America*, 117(11), 6129–6138. <https://doi.org/10.1073/pnas.1917820117>
- 1293 Studier, F. W., & Moffatt, B. A. (1986). Use of bacteriophage T7 RNA polymerase to direct  
1294 selective high-level expression of cloned genes. *Journal of Molecular Biology*,  
1295 189(1), 113–130. [https://doi.org/10.1016/0022-2836\(86\)90385-2](https://doi.org/10.1016/0022-2836(86)90385-2)
- 1296 Su, H.-N., Li, K., Zhao, L.-S., Yuan, X.-X., Zhang, M.-Y., Liu, S.-M., Chen, X.-L., Liu, L.-  
1297 N., & Zhang, Y.-Z. (2020). Structural Visualization of Septum Formation in  
1298 *Staphylococcus warneri* Using Atomic Force Microscopy. *Journal of Bacteriology*,  
1299 202(19). <https://doi.org/10.1128/JB.00294-20>
- 1300 Sutton, J. A. F., Carnell, O. T., Lafage, L., Gray, J., Biboy, J., Gibson, J. F., Pollitt, E. J. G.,  
1301 Tazoll, S. C., Turnbull, W., Hajdamowicz, N. H., Salamaga, B., Pidwill, G. R.,  
1302 Condliffe, A. M., Renshaw, S. A., Vollmer, W., & Foster, S. J. (2021).  
1303 *Staphylococcus aureus* cell wall structure and dynamics during host-pathogen  
1304 interaction. *PLoS Pathogens*, 17(3), e1009468.  
1305 <https://doi.org/10.1371/journal.ppat.1009468>
- 1306 Swoboda, J. G., Campbell, J., Meredith, T. C., & Walker, S. (2010). Wall teichoic acid  
1307 function, biosynthesis, and inhibition. *Chembiochem: A European Journal of*  
1308 *Chemical Biology*, 11(1), 35–45. <https://doi.org/10.1002/cbic.200900557>
- 1309 Taguchi, A., Welsh, M. A., Marmont, L. S., Lee, W., Sjodt, M., Kruse, A. C., Kahne, D.,  
1310 Bernhardt, T. G., & Walker, S. (2019). FtsW is a peptidoglycan polymerase that is  
1311 functional only in complex with its cognate penicillin-binding protein. *Nature*  
1312 *Microbiology*, 4(4), 587–594. <https://doi.org/10.1038/s41564-018-0345-x>
- 1313 Turner, R. D., Ratcliffe, E. C., Wheeler, R., Golestanian, R., Hobbs, J. K., & Foster, S. J.  
1314 (2010). Peptidoglycan architecture can specify division planes in *Staphylococcus*  
1315 *aureus*. *Nature Communications*, 1, 26. <https://doi.org/10.1038/ncomms1025>

- 1316 Turner, R. D., Vollmer, W., & Foster, S. J. (2014). Different walls for rods and balls: The  
1317 diversity of peptidoglycan. *Molecular Microbiology*, *91*(5), 862–874.  
1318 <https://doi.org/10.1111/mmi.12513>
- 1319 Typas, A., Banzhaf, M., Gross, C. A., & Vollmer, W. (2011). From the regulation of  
1320 peptidoglycan synthesis to bacterial growth and morphology. *Nature Reviews*.  
1321 *Microbiology*, *10*(2), 123–136. <https://doi.org/10.1038/nrmicro2677>
- 1322 Vollmer, W., Blanot, D., & de Pedro, M. A. (2008). Peptidoglycan structure and architecture.  
1323 *FEMS Microbiology Reviews*, *32*(2), 149–167. [https://doi.org/10.1111/j.1574-](https://doi.org/10.1111/j.1574-6976.2007.00094.x)  
1324 [6976.2007.00094.x](https://doi.org/10.1111/j.1574-6976.2007.00094.x)
- 1325 Weidenmaier, C., Peschel, A., Xiong, Y.-Q., Kristian, S. A., Dietz, K., Yeaman, M. R., &  
1326 Bayer, A. S. (2005). Lack of wall teichoic acids in *Staphylococcus aureus* leads to  
1327 reduced interactions with endothelial cells and to attenuated virulence in a rabbit  
1328 model of endocarditis. *The Journal of Infectious Diseases*, *191*(10), 1771–1777.  
1329 <https://doi.org/10.1086/429692>
- 1330 Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan,  
1331 R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., McNicholas, S. J., Murshudov,  
1332 G. N., Pannu, N. S., Potterton, E. A., Powell, H. R., Read, R. J., Vagin, A., & Wilson,  
1333 K. S. (2011). Overview of the CCP4 suite and current developments. *Acta*  
1334 *Crystallographica. Section D, Biological Crystallography*, *67*(Pt 4), 235–242.  
1335 <https://doi.org/10.1107/S0907444910045749>
- 1336 Yang, Y., Bhachech, N., & Bush, K. (1995). Biochemical comparison of imipenem,  
1337 meropenem and biapenem: Permeability, binding to penicillin-binding proteins, and  
1338 stability to hydrolysis by beta-lactamases. *The Journal of Antimicrobial*  
1339 *Chemotherapy*, *35*(1), 75–84. <https://doi.org/10.1093/jac/35.1.75>

- 1340 Yeats, C., Finn, R. D., & Bateman, A. (2002). The PASTA domain: A beta-lactam-binding  
1341 domain. *Trends in Biochemical Sciences*, 27(9), 438. <https://doi.org/10.1016/s0968->  
1342 0004(02)02164-3
- 1343 Zapun, A., Contreras-Martel, C., & Vernet, T. (2008). Penicillin-binding proteins and beta-  
1344 lactam resistance. *FEMS Microbiology Reviews*, 32(2), 361–385.  
1345 <https://doi.org/10.1111/j.1574-6976.2007.00095.x>
- 1346 Zhao, G., Meier, T. I., Kahl, S. D., Gee, K. R., & Blaszcak, L. C. (1999). BOCILLIN FL, a  
1347 Sensitive and Commercially Available Reagent for Detection of Penicillin-Binding  
1348 Proteins. *Antimicrobial Agents and Chemotherapy*, 43(5), 1124–1128.
- 1349 Zhou, X., Halladin, D. K., Rojas, E. R., Koslover, E. F., Lee, T. K., Huang, K. C., & Theriot,  
1350 J. A. (2015). Bacterial division. Mechanical crack propagation drives millisecond  
1351 daughter cell separation in *Staphylococcus aureus*. *Science (New York, N.Y.)*,  
1352 348(6234), 574–578. <https://doi.org/10.1126/science.aaa1511>  
1353

1354 **Appendix Tables**

1355 **Appendix Table 1. Strains used in this study**

Name	Relevant genotype/Markers	Source
<i>Staphylococcus aureus</i>		
SH1000	Functional <i>rsbU</i> <sup>+</sup> derivative of <i>S. aureus</i> 8325-4	(Horsburgh et al., 2002)
VF17	SH1000 pGL485 ( <i>lacI</i> ); Cm <sup>R</sup>	(Steele et al., 2011)
RN4220	Restriction deficient transformation recipient	(Kreiswirth et al., 1983)
CYL316	RN4220 pCL112Δ19	(Lee et al., 1991)
SJF4588	SH1000 <i>geh::Pspac-pbpI</i> ; Tet <sup>R</sup>	This study
SJF5116	SH1000 <i>geh::Pspac -pbpI ΔpbpI</i> ; Tet <sup>R</sup>	This study
SJF5275	SH1000 <i>geh::Pspac -pbpI pbpI</i> <sub>ΔPASTA</sub> ; Tet <sup>R</sup>	This study
SJF4590	SH1000 <i>geh::Pspac -pbpI pbpI*</i> Tet <sup>R</sup> , Cm <sup>R</sup>	This study
<i>ΔpbpI</i>	SH1000 <i>geh::Pspac -pbpI ΔpbpI lacI</i> ; Tet <sup>R</sup>	This study
<i>pbpI</i> <sub>ΔPASTA</sub>	SH1000 <i>geh::Pspac -pbpI pbpI</i> <sub>ΔPASTA</sub> <i>lacI</i> ; Tet <sup>R</sup> , Cm <sup>R</sup>	This study
<i>pbpI*</i>	SH1000 <i>geh::Pspac -pbpI pbpI*</i> <i>lacI</i> ; Tet <sup>R</sup> , Cm <sup>R</sup>	This study
SJF5046	SH1000 <i>lysA::pmecA rpoB</i> <sup>H929Q</sup> ; Ery <sup>R</sup> , Kan <sup>R</sup>	(Panchal et al., 2020)
<i>ΔpbpI pmecA</i>	SH1000 <i>geh::Pspac-pbpI ΔpbpI lacI lysA::pmecA</i> ; Tet <sup>R</sup> , Cm <sup>R</sup> , Ery <sup>R</sup>	This study
<i>pbpI* pmecA</i>	SH1000 <i>geh::Pspac-pbpI pbpI* lacI lysA::pmecA</i> ; Tet <sup>R</sup> , Cm <sup>R</sup> , Ery <sup>R</sup>	This study
MRSA <i>ΔpbpI</i>	SH1000 <i>geh::Pspac-pbpI ΔpbpI lacI lysA::pmecA rpoB</i> <sup>H929Q</sup> ; Tet <sup>R</sup> , Cm <sup>R</sup> , Ery <sup>R</sup> , Kan <sup>R</sup>	This study
MRSA <i>pbpI*</i>	SH1000 <i>geh::Pspac-pbpI pbpI* lacI lysA::pmecA rpoB</i> <sup>H929Q</sup> ; Tet <sup>R</sup> , Cm <sup>R</sup> , Ery <sup>R</sup> , Kan <sup>R</sup>	This study
JGL227	SH1000 <i>ezaA-gfp</i> <sup>+</sup> ; Ery <sup>R</sup>	(Steele et al., 2011)
<i>ΔpbpI ezaA-gfp</i>	SH1000 <i>geh::Pspac-pbpI ΔpbpI lacI ezaA-gfp</i> ; Tet <sup>R</sup> , Cm <sup>R</sup> , Ery <sup>R</sup>	This study
<i>pbpI</i> <sub>ΔPASTA</sub> <i>ezaA-gfp</i>	SH1000 <i>geh::Pspac-pbpI pbpI</i> <sub>ΔPASTA</sub> <i>lacI ezaA-gfp</i> ; Tet <sup>R</sup> , Cm <sup>R</sup> , Ery <sup>R</sup>	This study



<i>pbp1* ezrA-gfp</i>	SH1000 <i>geh::Pspac-pbp1 pbp1* lacI ezrA-gfp</i> ; Tet <sup>R</sup> , Cm <sup>R</sup> , Ery <sup>R</sup>	This study
NE420	JE2 <i>pbp3::Tn</i> ; Ery <sup>R</sup>	(Fey et al., 2013)
SH4421	SH1000 <i>pbp3::Tn</i> ; Ery <sup>R</sup>	This study
NE3004	RN4220 pKAN; Cm <sup>R</sup> , Ery <sup>R</sup>	(Fey et al., 2013)
SH4425	<i>pbp4::Tn</i> ; Ery <sup>R</sup>	(Lund et al., 2018)
SH5115	SH1000 <i>pbp4::kan</i> ; Kan <sup>R</sup>	This study
<i>pbp3 pbp4</i> (SH5483)	<i>pbp3::Tn pbp4::kan</i> ; Ery <sup>R</sup> , Kan <sup>R</sup> ,	This study
$\Delta$ <i>pbp1 pbp4</i>	SH1000 <i>geh::Pspac-pbp1 <math>\Delta</math>pbp1 lacI pbp4::Tn</i> ; Tet <sup>R</sup> , Cm <sup>R</sup> , Kan <sup>R</sup>	This study
<i>pbp1</i> $\Delta$ PASTA <i>pbp4</i>	SH1000 <i>geh::Pspac-pbp1 pbp1</i> $\Delta$ PASTA <i>lacI pbp4::Tn</i> ; Tet <sup>R</sup> , Cm <sup>R</sup> , Kan <sup>R</sup>	This study
<i>pbp1* pbp4</i>	SH1000 <i>geh::Pspac-pbp1 pbp1* lacI pbp4::Tn</i> ; Tet <sup>R</sup> , Cm <sup>R</sup> , Kan <sup>R</sup>	This study
<i>tarO</i>	SH1000 $\Delta$ <i>tarO::ery</i> ; Ery <sup>R</sup>	Constructed by Dr B. Salamaga (University of Sheffield)
<i>tarO tarO+</i>	SA113 $\Delta$ <i>tarO::ery</i> pUC1- <i>tarO</i> ; Ery <sup>R</sup> , Cm <sup>R</sup>	Constructed by Dr B. Salamaga (University of Sheffield)
$\Delta$ <i>pbp1 tarO</i>	SH1000 <i>geh::Pspac-pbp1 <math>\Delta</math>pbp1 lacI <math>\Delta</math>tarO::ery</i> ; Tet <sup>R</sup> , Cm <sup>R</sup> , Ery <sup>R</sup>	This study
<i>pbp1</i> $\Delta$ PASTA <i>tarO</i>	SH1000 <i>geh::Pspac-pbp1 pbp1</i> $\Delta$ PASTA <i>lacI <math>\Delta</math>tarO::ery</i> ; Tet <sup>R</sup> , Cm <sup>R</sup> , Ery <sup>R</sup>	This study
<i>pbp1* tarO</i>	SH1000 <i>geh::Pspac-pbp1 pbp1* lacI <math>\Delta</math>tarO::ery</i> ; Tet <sup>R</sup> , Cm <sup>R</sup> , Ery <sup>R</sup>	This study
<i>Escherichia coli</i>		
NEB5 $\alpha$	<i>fhuA2 (argF-lacZ)U169 phoA glnV44 80 (lacZ)M15 gyrA96 recA1 relA1 endA1 thi-1 hsdR17</i>	New England Biolabs
BTH101	<i>F<sup>-</sup>, cya-99, araD139, galE15, galK16, rpsL1, hsdR2, mcrA1, mcrB1</i>	(Karimova et al., 2001)
Rosetta (DE3)	<i>F<sup>-</sup> ompT hsdS<sub>B</sub>(r<sub>B</sub><sup>-</sup> m<sub>B</sub><sup>-</sup>) gal dcm</i> (DE3) pRARE (Cm <sup>R</sup> )	Novagen
BL21(DE3)	<i>F<sup>-</sup> ompT hsdS<sub>B</sub> (r<sub>B</sub><sup>-</sup>, m<sub>B</sub><sup>-</sup>) gal dcm</i> (DE3)	(Studier & Moffatt, 1986)

1357 **Appendix Table 2. Plasmids used in this study**

Name	Characteristics	Source
pCQ11-FtsZ-SNAP	pCQ11 derivative containing <i>ftsZ-snap</i> under <i>Pspac</i> ; Amp <sup>R</sup> , Ery <sup>R</sup>	(Lund et al., 2018)
pKASBAR	pUC18 containing <i>attP</i> and tetracycline cassette; Amp <sup>R</sup> , Tet <sup>R</sup>	(Bottomley et al., 2014)
pKB- <i>Pspac-pbp1</i>	pKASBAR containing <i>S. aureus pbp1</i> under <i>Pspac</i> ; Amp <sup>R</sup> , Tet <sup>R</sup>	This study
pMAD	<i>E. coli-S. aureus</i> shuttle vector with temperature-sensitive origin of replication in <i>S. aureus</i> and constitutively produced thermostable $\beta$ -galactosidase encoded by <i>bgaB</i> ; Amp <sup>R</sup> , Ery <sup>R</sup>	(Arnaud et al., 2004)
pMAD- $\Delta$ <i>pbp1</i>	pMAD containing a deletion cassette for <i>S. aureus pbp1</i> ; Amp <sup>R</sup> , Ery <sup>R</sup>	This study
pMAD- <i>pbp1</i> $\Delta$ PASTA	pMAD containing a deletion cassette for <i>S. aureus pbp1</i> PASTA domains; Amp <sup>R</sup> , Ery <sup>R</sup>	This study
pMAD- <i>pbp1</i> *	pMAD containing a cassette for introduction of a point mutation (S314A) in the active site <i>S. aureus pbp1</i> ; Amp <sup>R</sup> , Ery <sup>R</sup>	This study
pGL485	<i>E. coli-S. aureus</i> shuttle vector carrying <i>E. coli lacI</i> gene under the control of a constitutive promoter; Spec <sup>R</sup> , Cam <sup>R</sup>	(Cooper et al., 2009)
T18 (pUT18C)	Derivative of high copy-number pUC19, carrying gene encoding amino acids 225 to 399 of CyaA (T18 fragment); Amp <sup>R</sup>	(Karimova et al., 2001)
T18-zip (pUT18C-zip)	pUT18C coding for the leucine zipper region of the GCN4 yeast protein. Positive control; Amp <sup>R</sup>	(Karimova et al., 2001)
EzrA-T18 (pVF32)	pUT18(Karimova et al., 2001) containing T18 fused in frame to the 3' end of <i>S. aureus ezrA</i> ; Amp <sup>R</sup>	(Steele et al., 2011)
T18-PBP2 (pGL547)	pUT18C containing T18 fused in frame to the 5' end of <i>S. aureus pbp2</i> ; Amp <sup>R</sup>	(Steele et al., 2011)
T18-DivIC (pGL564)	pUT18C containing T18 fused in frame to the 5' end of <i>S. aureus divIC</i> ; Amp <sup>R</sup>	(Steele et al., 2011)
T18-DivIB (pGL544)	pUT18C containing T18 fused in frame to the 5' end of <i>S. aureus divIB</i> ; Amp <sup>R</sup>	(Steele et al., 2011)
T18-FtsW (pALB6)	pUT18C containing T18 fused in frame to the 5' end of <i>S. aureus ftsW</i> ; Amp <sup>R</sup>	(Steele et al., 2011)
T25 (pKT25)	Derivative of low copy-number pSU40, carrying the first 224 amino acids of <i>B. subtilis</i> CyaA (T25 fragment); Kan <sup>R</sup>	(Karimova et al., 2001)

T25-zip (pKT25-zip)	pKT25 coding for the leucine zipper region of the GCN4 yeast protein. Positive control; Kan <sup>R</sup>	(Karimova et al., 2001)
T25-PBP1 (pGL550)	pKT25 containing T25 fused in frame to the 5' end of <i>S. aureus pbp1</i> ; Kan <sup>R</sup>	(Steele et al., 2011)
T25-PBP1 <sub>ΔPASTA</sub>	pKT25 containing T25 fused in frame to the 5' end of <i>S. aureus pbp1</i> <sub>ΔPASTA</sub> (M1-S595); Kan <sup>R</sup>	This study
pOPINRSF	<i>kan P<sub>T7</sub> lacI</i> ; Kan <sup>R</sup>	(Berrow et al., 2009)
pVR01	<i>kan P<sub>T7</sub> pbp1 lacI</i> ; pOPINRSF derivative for overexpression of full length <i>S. aureus</i> PBP1 (1-744); Kan <sup>R</sup>	This study
pVR02	<i>kan P<sub>T7</sub> pbp1(37-744) lacI</i> ; pOPINRSF derivative for overexpression of SaPBP1 (37-744); Kan <sup>R</sup>	This study.
pVR03	<i>kan P<sub>T7</sub> pbp1*(37-744: S314A) lacI</i> ; pOPINRSF derivative for overexpression of SaPBP1* (37-744); Kan <sup>R</sup>	This study
pVR04	<i>kan P<sub>T7</sub> pbp1(37-595) lacI</i> ; pOPINRSF derivative for overexpression of SaPBP1 <sub>ΔPASTA</sub> (37-595); Kan <sup>R</sup>	This study
pVR06	<i>kan P<sub>T7</sub> pbp1(595-744) lacI</i> ; pOPINRSF derivative for overexpression of SaPASTA <sub>PBP1</sub> (595-744); Kan <sup>R</sup>	This study
pOPINJB	<i>bla P<sub>T7</sub> lacI</i> ; Amp <sup>R</sup>	(Berrow et al., 2009)
pSA50	pOPINJB derivative for overexpression of sPBP1A-BAP; Amp <sup>R</sup>	This study

1359 **Appendix Table 3. Oligonucleotides used in this study**

Name	5'-3' oligonucleotide sequence
pCQ-pbp1-F	AGAAGGAGATATACATATGGCTTGAGAACGATAATGTAAAG
pCQ-pbp1-F	TATTATGCATTTAGAATAGGTTAGTCCGACTTATCCTTG
pKB-Pspac-pbp1-F	CCTTTTTTTGCCCCGGGATCCGCAAAAAGTTGTTGACTTTATC
pKB-Pspac-pbp1-R	CTATGACCATGATTACGAATTCTTAGTCCGACTTATCCTTG
pbp1-A	CCATGGTACCCGGGAGCTCGCACCATGACGCAACATTAG
pbp1-B	ATCCTTGTCATTAATTTTTTGCTTCGCC
pbp1-C	CAAAAATTAATGACAAGGATAAGTCGGAC
pbp1-D	CCTCGCGTCGGGCGATATCGATCTCCATAAACACTTTAGC
pbp1-E	CCATGGTACCCGGGAGCTCGAATTCTAAAAACCTAGGCAATG
pbp1-F	TATCCTTGTCAGATGTGTCATCTTTTGATTTAC
pbp1-G	TGACACATCTGACAAGGATAAGTCGGACTAAC
pbp1-H	GCGTCTGCAGAAGCTTCTAGTTAATGCACTCCAATCCATAAAC
pbp1*5'-F	CCATGGTACCCGGGAGCTCGAATTCAGTATACCGAAGCAACAACCAC
pbp1*5'-R	TTAAATGTTGCTCCAGGCTCGTATGTGTTTTG
pbp1*3'-F	GAGCCTGGAGCAACATTTAAATCAT ATGGGTTA
pbp1*3'-R	CCTCGCGTCGGGCGATATCGGATCCTTAGTCCGACTTATCCTTGTC
T25-pbp1-F	CTGCAGGGTCGACTCTAGAGATGGCGAAGCAAAAAATTAA AATTAAAAAATAAAATAG
T25-pbp1pasta-R	ACGTTGTAAAACGACGGCCGTTAAGATGTGTCATCTTTGATTTACCTACATTTAAATATTC
VR47F	AAGTTCTGTTTCAGGGCCCGGCGAAGCAGAAGATCAAGATTAAGAAAAAC
VR47R	ATGGTCTAGAAAGCTTTAATCGCTTTTATCCTTGTCGGTTT TGC
VR49F	ATGATTACCGGCCACAGCAAC
VR49R	CGGGCCCTGAAACAGAACTTCCAG
VR51	AACACCTATGAGCCGGGCGCCACCTTCAAAGCTATGGTC
VR53	GAGCAAAGACGATAACCAGCTAAGCGGAGTACAGCAAGG
VR57F	AGCAACGCGGAGTACAGCAAGGTGCCGGACGTTG

OPPF20018F	AAGTTCTGTTTCAGGGCCCGGCGAACGAGAAATACCTGGT TAAGAACGCGC
OPPF20018R	AGATGTCGTTTCAGGCCATCGCTTTTATCCTTGTCGGTTTTG CTGTCGC

1360

1361 **Appendix Table 4. Crystallographic data**

<b>SaPASTA<sub>PBP1</sub></b>	
<b>Data</b>	
Resolution (Å)	1.78
Space group	<i>P2<sub>1</sub>2<sub>1</sub>2<sub>1</sub></i>
<i>a, b, c</i> (Å)	39.8, 81.4, 89.6
$\alpha, \beta, \gamma$ (°)	90, 90, 90
$\langle I/\sigma I \rangle^a$	14.2 (2.0)
Completeness (%) <sup>a</sup>	99.9 (99.8)
Redundancy <sup>a</sup>	7.7 (6.7)
$R_{p.i.m}$ (%) <sup>a</sup>	3.0 (39.1)
$R_{merge}$ (%) <sup>a</sup>	6.0 (66.0)
$CC_{1/2}$ <sup>a</sup>	99.8 (92.3)
<b>Refinement</b>	
$R_{work}$ (%)	18.7 %
$R_{free}$ (%) <sup>b</sup>	21.0 %
No. of residues	Chain A: 116, Chain B: 117
No. of waters	123
Average <i>B</i> -factor (Å <sup>2</sup> )	
Protein	Chain A: 45.1, Chain B: 48.0
Waters	47.6
R.m.s.d on ideal values	
Bond lengths (Å)	0.005
Bond angle (°)	0.755
<b>Ramachandran</b>	
Most favoured (%)	98.69
Additional allowed (%)	1.31
Outliers (%)	0.0
PDB ID	7O61

1362 <sup>a</sup>Values in parentheses are for the highest resolution shell.

1363 <sup>b</sup>For determination of  $R_{free}$ , 5 % of reflections were randomly selected before refinement.